ZA200210304B - Neuroprotective peptides. - Google Patents
Neuroprotective peptides. Download PDFInfo
- Publication number
- ZA200210304B ZA200210304B ZA200210304A ZA200210304A ZA200210304B ZA 200210304 B ZA200210304 B ZA 200210304B ZA 200210304 A ZA200210304 A ZA 200210304A ZA 200210304 A ZA200210304 A ZA 200210304A ZA 200210304 B ZA200210304 B ZA 200210304B
- Authority
- ZA
- South Africa
- Prior art keywords
- seq
- emp
- aka
- agonist
- amino acids
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 97
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 49
- 230000000324 neuroprotective effect Effects 0.000 title claims description 12
- 210000004027 cell Anatomy 0.000 claims description 98
- 238000000034 method Methods 0.000 claims description 71
- 150000001413 amino acids Chemical class 0.000 claims description 52
- 239000000556 agonist Substances 0.000 claims description 50
- 238000011282 treatment Methods 0.000 claims description 48
- 239000000539 dimer Substances 0.000 claims description 47
- 239000000203 mixture Substances 0.000 claims description 44
- 239000000126 substance Substances 0.000 claims description 40
- 150000008575 L-amino acids Chemical class 0.000 claims description 28
- 102000005962 receptors Human genes 0.000 claims description 19
- 108010001857 Cell Surface Receptors Proteins 0.000 claims description 17
- 102000006240 membrane receptors Human genes 0.000 claims description 17
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 102100033183 Epithelial membrane protein 1 Human genes 0.000 claims description 14
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims description 14
- 230000004071 biological effect Effects 0.000 claims description 13
- 108010008594 epithelial membrane protein-1 Proteins 0.000 claims description 13
- 229910052717 sulfur Inorganic materials 0.000 claims description 12
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 10
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 10
- 230000000926 neurological effect Effects 0.000 claims description 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 239000002202 Polyethylene glycol Substances 0.000 claims description 8
- 229920001223 polyethylene glycol Polymers 0.000 claims description 8
- 230000006378 damage Effects 0.000 claims description 7
- 229940044601 receptor agonist Drugs 0.000 claims description 7
- 239000000018 receptor agonist Substances 0.000 claims description 7
- 125000002849 D-tyrosine group Chemical group [H]N([H])[C@@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 230000004770 neurodegeneration Effects 0.000 claims description 5
- 150000008574 D-amino acids Chemical class 0.000 claims description 4
- 102100036509 Erythropoietin receptor Human genes 0.000 claims description 4
- 101100225851 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) emp-7 gene Proteins 0.000 claims description 4
- 206010029350 Neurotoxicity Diseases 0.000 claims description 4
- 206010044221 Toxic encephalopathy Diseases 0.000 claims description 4
- 230000007135 neurotoxicity Effects 0.000 claims description 4
- 231100000228 neurotoxicity Toxicity 0.000 claims description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000002464 receptor antagonist Substances 0.000 claims description 2
- 229940044551 receptor antagonist Drugs 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims 18
- 102000036693 Thrombopoietin Human genes 0.000 claims 7
- 108010041111 Thrombopoietin Proteins 0.000 claims 7
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 6
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 claims 5
- 108010002386 Interleukin-3 Proteins 0.000 claims 4
- 108010002616 Interleukin-5 Proteins 0.000 claims 4
- 108090001005 Interleukin-6 Proteins 0.000 claims 4
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 3
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 3
- 229940124753 IL-2 agonist Drugs 0.000 claims 3
- 102000004877 Insulin Human genes 0.000 claims 3
- 108090001061 Insulin Proteins 0.000 claims 3
- 230000003213 activating effect Effects 0.000 claims 3
- 238000001727 in vivo Methods 0.000 claims 3
- 229940125396 insulin Drugs 0.000 claims 3
- 229910052698 phosphorus Inorganic materials 0.000 claims 2
- BXRNXXXXHLBUKK-UHFFFAOYSA-N piperazine-2,5-dione Chemical compound O=C1CNC(=O)CN1 BXRNXXXXHLBUKK-UHFFFAOYSA-N 0.000 claims 2
- 101710102442 Erythropoietin receptor Proteins 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 230000000447 dimerizing effect Effects 0.000 claims 1
- 239000000492 insulin antagonist Substances 0.000 claims 1
- 229940105423 erythropoietin Drugs 0.000 description 107
- 102000003951 Erythropoietin Human genes 0.000 description 106
- 108090000394 Erythropoietin Proteins 0.000 description 106
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 103
- 241000700159 Rattus Species 0.000 description 49
- 230000014511 neuron projection development Effects 0.000 description 37
- 230000000694 effects Effects 0.000 description 28
- 230000001054 cortical effect Effects 0.000 description 26
- 108010025020 Nerve Growth Factor Proteins 0.000 description 24
- 102000015336 Nerve Growth Factor Human genes 0.000 description 24
- 229940053128 nerve growth factor Drugs 0.000 description 24
- 230000000971 hippocampal effect Effects 0.000 description 23
- 235000001014 amino acid Nutrition 0.000 description 21
- 229940024606 amino acid Drugs 0.000 description 21
- 239000003102 growth factor Substances 0.000 description 21
- 239000003981 vehicle Substances 0.000 description 21
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 20
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 18
- 230000001537 neural effect Effects 0.000 description 16
- 239000012981 Hank's balanced salt solution Substances 0.000 description 15
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 15
- 230000000302 ischemic effect Effects 0.000 description 15
- 210000002569 neuron Anatomy 0.000 description 15
- 108010074604 Epoetin Alfa Proteins 0.000 description 14
- 229930195712 glutamate Natural products 0.000 description 14
- 201000001119 neuropathy Diseases 0.000 description 14
- 230000007823 neuropathy Effects 0.000 description 14
- 230000004044 response Effects 0.000 description 14
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 13
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 12
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 12
- 102000044890 human EPO Human genes 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 230000002490 cerebral effect Effects 0.000 description 11
- 108020003175 receptors Proteins 0.000 description 11
- 229960003388 epoetin alfa Drugs 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000004112 neuroprotection Effects 0.000 description 9
- 230000001737 promoting effect Effects 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 102100021758 E3 ubiquitin-protein transferase MAEA Human genes 0.000 description 8
- 101000616009 Homo sapiens E3 ubiquitin-protein transferase MAEA Proteins 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000012737 fresh medium Substances 0.000 description 8
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 239000012091 fetal bovine serum Substances 0.000 description 7
- 230000036470 plasma concentration Effects 0.000 description 7
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 6
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 6
- 210000003618 cortical neuron Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 210000003754 fetus Anatomy 0.000 description 6
- 230000007574 infarction Effects 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 206010021143 Hypoxia Diseases 0.000 description 5
- 206010061216 Infarction Diseases 0.000 description 5
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 230000003394 haemopoietic effect Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 208000037906 ischaemic injury Diseases 0.000 description 5
- 210000000653 nervous system Anatomy 0.000 description 5
- 208000015122 neurodegenerative disease Diseases 0.000 description 5
- 238000003757 reverse transcription PCR Methods 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 4
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 4
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 4
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 4
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 4
- 108090000192 Methionyl aminopeptidases Proteins 0.000 description 4
- 102100021118 Microtubule-associated protein 2 Human genes 0.000 description 4
- 108090000742 Neurotrophin 3 Proteins 0.000 description 4
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 208000007502 anemia Diseases 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000003204 osmotic effect Effects 0.000 description 4
- 208000028591 pheochromocytoma Diseases 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 229940054269 sodium pyruvate Drugs 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 3
- 108010019673 Darbepoetin alfa Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 108010075944 Erythropoietin Receptors Proteins 0.000 description 3
- 206010015548 Euthanasia Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 239000012998 Hepes-buffered hanks’ balanced salt solution Substances 0.000 description 3
- 229930182816 L-glutamine Natural products 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 208000003954 Spinal Muscular Atrophies of Childhood Diseases 0.000 description 3
- 101710162629 Trypsin inhibitor Proteins 0.000 description 3
- 229940122618 Trypsin inhibitor Drugs 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 210000001130 astrocyte Anatomy 0.000 description 3
- 230000003542 behavioural effect Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 206010008118 cerebral infarction Diseases 0.000 description 3
- 208000020832 chronic kidney disease Diseases 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 3
- 229960003132 halothane Drugs 0.000 description 3
- 210000001320 hippocampus Anatomy 0.000 description 3
- 230000007954 hypoxia Effects 0.000 description 3
- 238000003365 immunocytochemistry Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 210000003061 neural cell Anatomy 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000002203 pretreatment Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000010410 reperfusion Effects 0.000 description 3
- 208000002320 spinal muscular atrophy Diseases 0.000 description 3
- 238000012453 sprague-dawley rat model Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000002753 trypsin inhibitor Substances 0.000 description 3
- 206010061666 Autonomic neuropathy Diseases 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 208000001730 Familial dysautonomia Diseases 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
- 208000027747 Kennedy disease Diseases 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- 208000034693 Laceration Diseases 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 description 2
- 108010020004 Microtubule-Associated Proteins Proteins 0.000 description 2
- 208000001089 Multiple system atrophy Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102000004230 Neurotrophin 3 Human genes 0.000 description 2
- 102000003683 Neurotrophin-4 Human genes 0.000 description 2
- 108090000099 Neurotrophin-4 Proteins 0.000 description 2
- 208000033526 Proximal spinal muscular atrophy type 3 Diseases 0.000 description 2
- 201000001638 Riley-Day syndrome Diseases 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 230000002424 anti-apoptotic effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000005016 dendritic process Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 201000004815 juvenile spinal muscular atrophy Diseases 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 208000005264 motor neuron disease Diseases 0.000 description 2
- 210000002241 neurite Anatomy 0.000 description 2
- 238000003522 neurite outgrowth assay Methods 0.000 description 2
- 230000000626 neurodegenerative effect Effects 0.000 description 2
- 208000029986 neuroepithelioma Diseases 0.000 description 2
- 230000006576 neuronal survival Effects 0.000 description 2
- 231100000189 neurotoxic Toxicity 0.000 description 2
- 230000002887 neurotoxic effect Effects 0.000 description 2
- 229940032018 neurotrophin 3 Drugs 0.000 description 2
- 229940097998 neurotrophin 4 Drugs 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000000861 pro-apoptotic effect Effects 0.000 description 2
- 229940029359 procrit Drugs 0.000 description 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000000946 synaptic effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 208000032527 type III spinal muscular atrophy Diseases 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 2
- 229960002555 zidovudine Drugs 0.000 description 2
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- LMYNKFDVIZBWDF-UHFFFAOYSA-N 2-azaniumyl-4-bromobutanoate Chemical compound OC(=O)C(N)CCBr LMYNKFDVIZBWDF-UHFFFAOYSA-N 0.000 description 1
- 201000011452 Adrenoleukodystrophy Diseases 0.000 description 1
- 208000018126 Adrenomyeloneuropathy Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 101100369978 Arabidopsis thaliana TMN11 gene Proteins 0.000 description 1
- 101100369984 Arabidopsis thaliana TMN3 gene Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010003594 Ataxia telangiectasia Diseases 0.000 description 1
- 102000007371 Ataxin-3 Human genes 0.000 description 1
- 102000051485 Bcl-2 family Human genes 0.000 description 1
- 108700038897 Bcl-2 family Proteins 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010006542 Bulbar palsy Diseases 0.000 description 1
- 208000029402 Bulbospinal muscular atrophy Diseases 0.000 description 1
- 206010058842 Cerebrovascular insufficiency Diseases 0.000 description 1
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 1
- 206010057645 Chronic Inflammatory Demyelinating Polyradiculoneuropathy Diseases 0.000 description 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000033647 Classic progressive supranuclear palsy syndrome Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 229930182847 D-glutamic acid Natural products 0.000 description 1
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000024412 Friedreich ataxia Diseases 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102100032610 Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas Human genes 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 206010018985 Haemorrhage intracranial Diseases 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 1
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 description 1
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
- 101000850989 Homo sapiens Epithelial membrane protein 1 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000031814 IgA Vasculitis Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 208000008574 Intracranial Hemorrhages Diseases 0.000 description 1
- 206010022840 Intraventricular haemorrhage Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000002569 Machado-Joseph Disease Diseases 0.000 description 1
- 208000019090 Machado-Joseph disease type 3 Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010033885 Paraparesis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010034620 Peripheral sensory neuropathy Diseases 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 208000032319 Primary lateral sclerosis Diseases 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102100036197 Prosaposin Human genes 0.000 description 1
- 101710152403 Prosaposin Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 208000032225 Proximal spinal muscular atrophy type 1 Diseases 0.000 description 1
- 229910001260 Pt alloy Inorganic materials 0.000 description 1
- 241000442474 Pulsatilla vulgaris Species 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 208000019155 Radiation injury Diseases 0.000 description 1
- 208000005587 Refsum Disease Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- CGNLCCVKSWNSDG-UHFFFAOYSA-N SYBR Green I Chemical compound CN(C)CCCN(CCC)C1=CC(C=C2N(C3=CC=CC=C3S2)C)=C2C=CC=CC2=[N+]1C1=CC=CC=C1 CGNLCCVKSWNSDG-UHFFFAOYSA-N 0.000 description 1
- 208000021811 Sandhoff disease Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 208000009106 Shy-Drager Syndrome Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 208000002548 Spastic Paraparesis Diseases 0.000 description 1
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000032859 Synucleinopathies Diseases 0.000 description 1
- 208000018359 Systemic autoimmune disease Diseases 0.000 description 1
- 208000022292 Tay-Sachs disease Diseases 0.000 description 1
- 206010043395 Thalassaemia sickle cell Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 206010046298 Upper motor neurone lesion Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000026481 Werdnig-Hoffmann disease Diseases 0.000 description 1
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 208000030597 adult Refsum disease Diseases 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000012197 amplification kit Methods 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000005735 apoptotic response Effects 0.000 description 1
- 229940115115 aranesp Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000003210 demyelinating effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000000613 ear canal Anatomy 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000001037 epileptic effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 201000006061 fatal familial insomnia Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000008675 hereditary spastic paraplegia Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 201000009939 hypertensive encephalopathy Diseases 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 206010023497 kuru Diseases 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000003657 middle cerebral artery Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 208000020469 nerve plexus disease Diseases 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 210000003924 normoblast Anatomy 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 208000031237 olivopontocerebellar atrophy Diseases 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 201000005989 paraneoplastic polyneuropathy Diseases 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 238000011518 platinum-based chemotherapy Methods 0.000 description 1
- 201000006380 plexopathy Diseases 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 208000001282 primary progressive aphasia Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 208000032207 progressive 1 supranuclear palsy Diseases 0.000 description 1
- 201000002241 progressive bulbar palsy Diseases 0.000 description 1
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 description 1
- 208000027065 progressive myoclonus epilepsy 9 Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000031877 prophase Effects 0.000 description 1
- 201000000196 pseudobulbar palsy Diseases 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000001991 scapula Anatomy 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 201000005572 sensory peripheral neuropathy Diseases 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 230000001148 spastic effect Effects 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 208000003755 striatonigral degeneration Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002723 toxicity assay Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 208000032471 type 1 spinal muscular atrophy Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
- 210000000216 zygoma Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- AIDS & HIV (AREA)
- Biochemistry (AREA)
Description
NEUROPROTECTIVE PEPTIDES
This application claims the benefit of United States Provisional Application Serial
No. 60/207654, filed May 26, 2000.
The present invention is directed to methods of treating diseases and conditions involving the nervous system by administration of compositions having the therapeutic activity of human erythropoietin. These compositions include therapeutic agents such as peptides, peptide dimers, polypeptides, and proteins that have the full range of biological activity of human erythropoietin or only certain biological activities of erythropoietin. The present invention also provides improved therapeutic regimens wherein the therapeutic agent is administered at concentrations below those required to stimulate hematopoiesis.
Erythropoietin (EPO) is a glycoprotein hormone produced by the kidney in response to tissue hypoxia that stimulates red blood cell production in the bone marrow. The gene for erythropoietin has been cloned and expressed in Chinese hamster ovary (CHO) cells as described in United States Patent No. 4,703,008. Recombinant human erythropoietin (r-
HuEPO or Epoetin alfa) has an amino acid sequence identical to that of human urinary erythropoietin, and the two are indistinguishable in chemical, physical and immunological tests. Recombinant human erythropoietin acts by increasing the number of cells capable of , differentiating into mature erythrocytes, triggering their differentiation and augmenting hemoglobin synthesis in developing erythroblasts (Krantz SB. Blood (1991) 77: 419-434, 0 Beckman BS, Mason-Garcia M. The Faseb Journal (1991) 5: 2958-2964).
Epoetin alfa has been well tolerated in studies conducted to date. Hypertensive encephalopathy and seizures have occasionally been described in dialysis patients treated with
Epoetin alfa, particularly during the early phase of therapy when hematocrit is rising. (Eschbach
JW, Egrie JC, Downing MR, Browne JK, Adamson JW. New Engl J Med (1987) 316: 73-78, , 5 Winearls CG, Oliver DO, Pippard MJ, et al. Lancet (1986) 2 (8517): 1175-1177). Such reports became more rare as experience of use of the compound developed. Occasionally, cancer patients treated with Epoetin alfa have experienced an increase in blood pressure associated with a significant increase in hematocrit. The risk, however, appears substantially lower than in chronic renal failure patients.
No antibody titers against Epoetin alfa could be demonstrated and confirmed in subjects treated with Epoetin alfa for up to 2 years, indicating the absence of immunological sensitivity to
Epoetin alfa. Skin rashes and urticaria have been observed rarely and when reported have been mild and transient in nature, but these events suggest allergic hypersensitivity to some components of the Epoetin alfa formulation.
Epoetin alfa is approved for sale in many countries for the treatment of anemia in chronic renal failure (dialysis and predialysis), anemia in zidovudine treated HIV positive patients (US), anemia in cancer patients receiving platinum-based chemotherapy, as a facilitator of ° autologous blood pre-donation, and as a peri-surgical adjuvant to reduce the likelihood of requiring allogeneic blood transfusions in patients undergoing orthopedic surgery.
EPO influences neuronal stem cells, likely during embryonic development, and possibly during in vitro experiments of differentiation. (Juul et al Pediatr Dev Pathol (1999) 2(2) 148 — 158. Juul et al Pediatr Res (1998) 43(1) 40 — 49.) Further, neonates and infants that suffer CNS injury via hypoxia, meningitis, and intraventricular hemorrhage, show an
EPO induced neuroprotective effect (Juul et al Ped Res (1999) 46(5) 543 — 547.)
EPO helps prevent apoptosis of neural tissue in cases of injury that create hypoxia.
This may be the result of EPO produced locally by astrocytes (Morishita et al Neuroscience (1996) 76(1) 105 — 116). Neuroprotection has been demonstrated in gerbil hippocampal and rat cerebrocortical tissue (Sakanaka et al PNAS (1998) 95(8) 4635 — 4640. Sadamoto et al
Biochem Biophys Res Commun (1998) 253(1) 26 — 32).
EPO induces biological effects of PC12 cells, including changes in Ca®, changes in membrane potential, and promotion of neuronal survival. This has been interpreted that EPO can stimulate neural function and viability (Koshimura et al J. Neurochem (1999) 72(6) 2565-2572. Tabria et al Int J Dev Neurosci (1995) 13(3/4) 241 —252.).
O’Brien et al propose that a 17 amino acid peptide sequence of EPO can act through the EPO -R (Erythropoietin receptor) to induce biological activity in NS20Y, SK-N-MC, and
PC12 cells, which includes sprouting, differentiation and neuroprotection. Curiously this peptide does not promote proliferation of hematologic cells, thus it appears inactive in cell lines well understood for their sensitivity to EPO activity. (Campana et al Int J Mol Med (1998) 1(1) 235 — 241 and United States Patent No.’s 5,700,909, issued on 12/23/1999, 5,571,787, issued on 11/5/1996, 5,714,459, issued on 2/3/1998, and 5,696,080, issued on 12/9/1997, all to O’Brien et al.)
EPO may influence neuronal stem cell commitment to drive differentiation of neurons as opposed to astrocytes or oligodendrocytes. This is compared to a similar activity of EPO, where it functions to drive commitment of hematopoietic stem cells to produce red blood cells (RBCs). There is an apparent relationship between CNS hypoxic injury, resulting in the production of EPO from astrocytes that commits neuronal stem cells to differentiate into neurons, while simultaneously acting as a neuroprotective function for existing neurons. (WIPO publication number W099/21966, published on 5/6/1999, Weiss et al.)
‘ The present invention is directed to methods of treating diseases and conditions involving the nervous system by administration of compositions having the neurological therapeutic activity of human erythropoietin. oo
In a first embodiment, the present invention is directed to a method for treating a patient having a disorder characterized by neurotoxicity, neurodegeneration or neurological damage, comprising administering to said patient a therapeutically effective amount of a peptide comprising one or more monomeric peptides of 8 to about 40 amino acids in length that bind to EPO receptor, each monomeric peptide comprising a sequence of amino acids
X XX, XXX XX, (SEQ ID NO: 47), wherein
X,isGor A;
X,is Por A;
X,isTor A;
X, is selected from W, A, and F;
X, is selected from R, H, Y, L, and W, or X, is nonexistent;
X, is selected from F, M, and I;
X, is independently selected from the 20 genetically coded L-amino acids or the stereoisomeric D-amino acids; and
X, is selected from D, V, E, I, and L.
In particular, said sequence is X;X, X;GPX, TWX, X, (SEQ ID NO: 1), wherein
X, is selected from C, E, A, a-amino-y-bromobutyric acid, and homocysteine (Hoc); and
X, is selected from C, K, A, a-amino-y-bromobutyric acid, and homocysteine (Hoc).
In a second embodiment, the present invention is directed to peptides which behave as cell-surface receptor agonists and antagonists, as well as dimers and multimers ’ of such peptides which exhibit binding and signal initiation of growth factor-type receptors. In one embodiment, the present invention provides peptides which behave as ) 5 EPO agonists. These peptides may be dimers or multimers of such peptides, preferably 14 to about 20 residues in length, comprising a core amino acid sequence of X;X,
XGPXTITWX,X, (SEQ ID NO: 1) wherein each amino acid is indicated by standard one letter abbreviation; X; can be C, E, A, a-amino-y-bromobutyric acid, or Hoc, where Hoc is homocysteine; X, can be R, H, Y, L, or W, or X, is nonexistent; X; can be M, F, or I;
X; is independently any one of the 20 genetically coded L-amino acids or the stereoisomeric D-amino acids; X, can be D, E, I, L, or V; and X; can be C, K, A, a- amino-y-bromobutyric acid, or Hoc, where Hoc is homocysteine.
Preferably, the monomeric peptide unit of the dimer or multimer comprises a core sequence of amino acids YX, X;X, X,GPX,TWX,X; (SEQ ID NO: 2), wherein each of X, and
X, is independently any one of the 20 genetically coded L-amino acids; X; is C; and X, is C.
Preferably, the monomeric peptide unit of the dimer comprises a core sequence of amino acids X; YX, XX, X;GPX TWX, XXX, X,; (SEQ ID NO: 3), wherein each of X;, X,,
XX, Xo, and X,, is independently selected from the 20 genetically coded L-amino acids.
Particularly, X, can be C, E, A; X, can be R, H, or Y, or X, is nonexistent; X; can be M, F, or
I; X; can be D or V; and X; can be C, K, or A.
In a more preferred embodiment, both X; and X; are C and thus, the monomeric peptide unit of the dimer comprises a core sequence of amino acids X; YX, CX, X; GPX;
TWX, CX, Xo X,; (SEQ ID NO: 4). Particularly, the monomeric peptide unit comprises a core sequence of amino acids X, YX, CX, X; GPX; TWX, CX, X,, X;, (SEQ ID NO: ’ 5), where X, can be R or H; X; canbe F or M; X, canbe I, L, T, M, or V; X; is D or V;
Xg,canbe G,K,L, Q,R, S, or T; and X,, can be A, G, P, R, or Y. More particularly, the monomeric peptide unit of the dimer will comprise a core sequence of amino acids X,
YX, CX, X; GPX; TWX, CX, X;, X,;; (SEQ ID NO: 6), where X, canbe D, E, L, N, §,
T,orV; X, canbe A, H,K,L,M, S,or T; X, is R or H; X, can be K, R, S, or T; and X, is
P.
Preferably, the monomeric peptide unit of the dimer will comprise a core sequence of . 5 amino acids X, YX, CX, X; GPX; TWX, CX, X,, X,; (SEQ ID NO: 6), where X, can be D,
E,L,N,S, T,orV; X, canbe A, H, K,L,M, S, or T; X,is Ror H; X, canbe K, R, S, or T; and X,, is P.
Particularly preferred monomeric peptide units of the dimers include:
GGLYLCRFGPVTWDCGYKGG (SEQ ID NO:7);
GGTYSCHFGPLTWVCKPQGG (aka EMP-1) (SEQ ID NO:8);
GGDYHCRMGPLTWVCKPLGG (SEQ ID NO:9);
VGNYMCHFGPITWVCRPGGG (SEQ ID NO:10);
GGVYACRMGPITWVCSPLGG (SEQ ID NO:11);
VGNYMAHMGPITWVCRPGG (SEQ ID NO:12);
GGTYSCHFGPLTWVCKPQ (aka EMP-16) (SEQ ID NO:13);
GGLYACHMGPMTWVCQPLRG (aka EMP-36) (SEQ ID NO:14);
TIAQYICYMGPETWECRPSPKA (aka EMP-38) (SEQ ID NO:15); :
YSCHFGPLTWVCK (aka EMP-20 (SEQ ID NO:16);
YCHFGPLTWVC (aka EMP-23) (SEQ ID NO:17);
SCHFGPLTWVCK (aka EMP-24) (SEQ ID NO:18);
GGTASCHFGPLTWVCKPQGG (aka EMP-6) (SEQ ID NO:19);
GGTYSCHFAPLTWVCKPQGG (aka EMP-9) (SEQ ID NO:20);
GGTYSCFGPLTWVCKPQGG (aka EMP-27) (SEQ ID NO:21);
TYSCHFGPLTWVCKPQGG (aka EMP-17) (SEQ ID NO:22);
TYSCHFGPLTWVCKPQ (aka EMP-18) (SEQ ID NO:23);
YSCHFGPLTWVCKP (aka EMP-19) (SEQ ID NO:24);
YSCHFGPLTWVC (aka EMP-21) (SEQ ID NO:25); ] 30 YSCHFGALTWVCK (aka EMP-22) (SEQ ID NO:26);
GGCRIGPITWVCGG (aka EMP-25) (SEQ ID NO:27);
HFGPLTWV (aka EMP-26) (SEQ ID NO:28);
GGTTSCHFGPLTWVCKPQGG (aka EMP-7) (SEQ ID NO:29);
GGTFSCHFGPLTWVCKPQGG (aka EMP-8) (SEQ ID NO:30); ’ GGTYSCHFGALTWVCKPQGG (aka EMP-10) (SEQ ID NO:31);
GGTYSCHFGPATWVCKPQGG (aka EMP-11) (SEQ ID NO:32);
GGTYSCHFGPLAWVCKPQGG (aka EMP-12) (SEQ ID NO:33);
GGTYSCHFGPLTAVCKPQGG (aka EMP-13) (SEQ ID NO:34);
GGTYSCHFGPLTFVCKPQGG (aka EMP-14) (SEQ ID NO:35);
GGTYSCHFGPLTWVCKAQGG (aka EMP-15) (SEQ ID NO:36);
GGTXSCHFGPLTWVCKPQGG (aka EMP-28, X = D-Tyr) (SEQ ID NO:37);
GGTXSCHFGPLTWVCKPQGG (aka EMP-29, X = p-NO,-Phe) (SEQ ID NO:38);
GGTXSCHFGPLTWVCKPQGG (aka EMP-30, X = p-NH,-Phe) (SEQ ID NO:39);
GGTXSCHFGPLTWVCKPQGG (aka EMP-31, X = p-F-Phe) (SEQ ID NO:40);
GGTXSCHFGPLTWVCKPQGG (aka EMP-32, X = p-I-Phe) (SEQ ID NO:41);
GGTXSCHFGPLTWVCKPQGG (aka EMP-33, X = 3,5-dibromo-Tyr) (SEQ ID NO:42),
Ac-GGTYSCHFGPLTWVCKPQGG (aka EMP-34) (SEQ ID NO:43);
GGLYACHMGPMTWVCQPLGG (aka EMP-35) (SEQ ID NO:44);
LGRKYSCHFGPLTWVCQPAKKD (aka EMP-37) (SEQ ID NO:45); and
GGTYSEHFGPLTWVKKPQGG (aka EMP-39) (SEQ ID NO:46).
Preferably, monomeric peptide units of the dimers include:
GGTYSCHFGPLTWVCKPQGG (aka EMP-1) (SEQ ID NO:8);
GGTASCHFGPLTWVCKPQGG (aka EMP-6) (SEQ ID NO:19),
GGTYSCHFAPLTWVCKPQGG (aka EMP-9) (SEQ ID NO:20); and
YCHFGPLTWVC (aka EMP-23) (SEQ ID NO:17).
In accordance with the present invention the monomeric units of the dimers can be the same or different. ' In a preferred embodiment polyethylene glycol (PEG) may be employed as a linker to . 5 form the dimeric peptides of the present invention through a covalent bond.
In another embodiment, the present invention is directed to pharmaceutical compositions comprising at least one peptide of the invention and a pharmaceutical carrier to - be used in a method of treating or preventing neurotoxicity.
In a further embodiment, the present invention provides a method for therapeutically treating a mammal having a disease or condition resulting from a neurotoxic or neurodegenerative or neuro-damaging event by administration of at least one of the peptides of the present invention.
In a still further embodiment, a method for therapeutically treating a mammal having a neurotoxic, neuro-damaging or neurodegenerative condition which may be modulated by
EPO by using at least one of the peptides of the present invention is provided.
Figure 1 Panel A and Panel B show that EPO receptor is expressed in rat hippocampal and cortical cultures.
Figure 2 shows that EPO receptor is expressed in neuronal cell lines: PC12 and SK- N-MC cells.
Figure 3 shows EPO induced gene expression in PC12 cells. (Top) Total RNA isolated from PC-12 cells treated with 1 nm EPO for 24 hr was subject to RT-PCR to quantify the changes in gene expression of specific BCL family members. Pre-treatment with
EPO resulted in a 6 fold increase in the expression of the anti-apoptotic gene BCL, and a } 30 greater than 5 fold decrease in the expression of the pro-apoptotic Bak. These results are consistent with the gene chip results suggesting a possible mechanism for EPO’s protective effects. (Bottom) Agarose gels showing RT-PCR products representing the regulation of ‘
Bcly and Bak. m — markers, 1 — RT-PCR negative control, lane 2 — No Treatment, lane 3 — 50 ng/ml NGF, lane 4 — EPO 1 nm. ' Figure 4 shows that rhEPO protects rat cerebral cortical neurons against glutamate toxicity.
Figure 5 shows that thEPO protects rat PCI2 cells against glutamate-induced cell death. 7 day cultures of PC-12 cells were treated with erythropoietin for 24 hours before being exposed to a toxic concentration of glutamate (200 um). Cultures were allowed to recover for 24 hours and cell survival was determined using a Trypan Blue exclusion assay. 1 to 10 pm Erythropoietin given 24 hours prior to a 15 minute exposure to glutamate significantly increased cell survival (p<.001, student’s t-test. The protective activity of EPO decreased at higher doses.
Figure 6 shows that rhEPO protects rat PC12 cells against NGF withdrawal-induced cell death. Cultures of PC-12 cells were grown in the presence of NGF for 7 days and then treated with EPO for 24 hours before they were switched to media without NGF. Cell survival was determined by counting the number of viable cells immediately following the removal of NGF and comparing it to the number of viable cells at 12 hr, 24 hr, 48 hr and 72 hr following growth factor withdrawal. Cell viability was determined based on morphological characteristics including phase brightness, presence of axons and absence of membrane blebbing. Treatment with EPO increased the number of viable cells at each time point following growth factor withdrawal with an optimum concentration of 10 pm.
Figure 7 shows that thEPO promotes neurite outgrowth in rat cerebral cultures.
Figure 8 shows that thEPO promotes neurite outgrowth in rat hippocampal cultures.
Figure 9 shows that EMP-1 promotes neurite outgrowth in rat cerebral cortical cultures.
Figure 10 shows that EMP-1 promotes neurite outgrowth in rat hippocampal cultures.
Figure 11 shows that EMP-6 promotes neurite outgrowth in rat cerebral cortical cultures.
Figure 12 shows that EMP-6 promotes neurite outgrowth in rat hippocampal cultures.
Figure 13 shows that EMP-9 promotes neurite outgrowth in rat cerebral cortical cultures.
Figure 14 shows that EMP-9 promotes neurite outgrowth in rat hippocampal cultures.
Figure 15 shows that EMP-23 promotes neurite outgrowth in rat cerebral cortical cultures.
Figure 16 shows that EMP-23 promotes neurite outgrowth in rat hippocampal cultures. . 5 Figure 17 shows that EMP-27 promotes neurite outgrowth in rat cerebral cortical cultures.
Figure 18 shows that EMP-27 promotes neurite outgrowth in rat hippocampal cultures.
Figure 19 shows that EPO protects against ischemic injury: study I continuous iv infusion via osmotic mini-pump.
Figure 20 shows plasma determinations for study I.
Figure 21 shows that EPO does not protect against ischemic injury: study II single iv bolus dose.
Figure 22 shows plasma determinations for study II.
Figure 23 shows that EPO protects against ischemic injury: study III repeat iv bolus dosing.
Figure 24 shows plasma determinations: study III.
"Erythropoietin" (EPO) used herein includes those peptides, peptide dimers, polypeptides, and proteins that have the full range of biological activity (for example, hematopoietic and neurological activities) of human erythropoietin or only certain biological activities (for example, hematopoietic or neurological activities only) of erythropoietin, as well as erythropoietin analogs, erythropoietin isoforms, erythropoietin mimetics, erythropoietin fragments, hybrid erythropoietin proteins, fusion proteins, oligomers and multimers of the above, homologues of the above, glycosylation pattern variants of the above, and muteins of the above, regardless of the biological activity of same, and further regardless of the method of synthesis or manufacture thereof including, but not limited to, recombinant, whether produced from cDNA or genomic DNA, synthetic, transgenic, and gene activated methods. Specific examples of erythropoietin include, Epoetin alfa (EPREX®,
ERYPO®, PROCRIT®), NEORECORMON, Novel erythropoiesis stimulating protein (NESP or ARANESP, a hyperglycosylated analog of recombinant human erythropoietin (Epoetin) described in European patent application EP640619), human erythropoietin analog — human : serum albumin fusion proteins such as those described in the international patent application
WO 99/66054, erythropoietin mutants such as those described in the international patent ) 5 application WO 99/38890, erythropoietin omega, which may be produced from an Apa 1 restriction fragment of the human erythropoietin gene described in United States Patent No. 5,688,679, altered glycosylated human erythropoietin such as those described in the international patent application WO 99/11781, PEG conjugated erythropoietin analogs such as those described in WO 98/05363 or United States Patent No. 5,643,575. Specific examples of cell lines modified for expression of endogenous human erythropoietin are described in international patent applications WO 99/05268 and WO 94/12650. The generally preferred form of EPO is purified, recombinant human EPO (thEPO), currently formulated and distributed under the trademarks of EPREX®, ERYPO®, or PROCRIT®.
The abbreviation “EMP” as used herein refers to peptide mimetics of EPO, particularly certain peptides described in United States Patent No.’s 5,767,078 and 5,773,569.
Following is a list of amino acid abbreviations used in the present specification for various peptides. The individual amino acid residues are identified according to a single letter and three letter code that is readily known and used by those of ordinary skill in the art.
AMINO ACID ABBREVIATIONS
3-Letter 1-Letter alanine ala A valine val Vv leucine leu L isoleucine ile I proline pro P g phenylalanine phe F tryptophan trp Ww methionine met M glycine gly G serine ser S threonine thr T cysteine Cys C tyrosine tyr Y asparagine asn N olutamine gln Q aspartic acid asp D glutamic acid glu E lysine lys K arginine arg R : histidine his H
In a first embodiment, the present invention is directed to methods of treating neuronal cells with a pharmaceutical composition comprising a therapeutically active peptide that behaves as cell-surface receptor agonists as well as dimers and multimers of such peptides that exhibit binding and signal initiation of growth factor-type receptors. In one embodiment, the present invention provides peptides that behave as EPO agonists.
Particularly, these peptides may be dimers or multimers that have two ‘monomeric’ peptide units of 8 to 40 or more amino acids, preferably 14 to about 20 residues in length, comprising a core amino acid sequence of X; X, X; GPX, TWX, X, (SEQ ID NO: 1) where each amino acid is indicated by standard one letter abbreviation; X; can be C, E, A, a-amino-y- bromobutyric acid, or Hoc, where Hoc is homocysteine; X, can be R, H, Y, L, or W, or X, is nonexistent; Xs can be M, F, or I; X; is independently any one of the 20 genetically coded L- amino acids or the stereoisomeric D-amino acids; X,; canbe D, E, I, L, or V; and X; can be C,
K, A, a-amino-y-bromobutyric acid, or Hoc, where Hoc is homocysteine, provided that either
X, or Xz is C or Hoc. Preferably, the monomeric peptide unit of the dimer or multimer comprises a core sequence YX,X,X,X;GPX,TWX,X; (SEQ ID NO: 2) where each amino acid is indicated by standard one letter abbreviation; each X,, X,, X;, Xo, X,q, and Xj; is independently selected from the 20 genetically coded L-amino acids; X; can be C, E, A, a- } 30 amino-y-bromobutyric acid, or Hoc, where Hoc is homocysteine; X, can be R, H, Y, L, or W, or X, is nonexistent; Xs canbe M, F, or I; X, can be D, E, I, L, or V; and X; can be C, K, A,
o-amino-y-bromobutyric acid, or Hoc, where Hoc is homocysteine. More preferably, either
X; or X; is C or Hoc.
Preferably, the monomeric peptide unit of the dimer or multimer comprises a core sequence of amino acids YX,X;X,X;GPX,TWX,X; (SEQ ID NO: 2), wherein each of X, and
X, is independently any one of the 20 genetically coded L-amino acids; X, is C; and Xj is C.
Preferably, the monomeric peptide unit of the dimer comprises a core sequence of amino acids X, YX,X;X,X,GPX, TWX, XX; X,,X,; (SEQ ID NO: 3), wherein each of X,, X,,
X,, Xo Xp, and X; is independently selected from the 20 genetically coded L-amino acids.
Particularly, X; can be C, E, A; X, can be R, H, or Y, or X, is nonexistent; X; can be M, F, or
I; X; can be D or V; and X; can be C, K, or A.
In a more preferred embodiment, both X; and X; are C and thus, the monomeric peptide unit of the dimer comprises a core sequence of amino acids X; YX, CX, X; GPX,
TWX, CX, Xo X;; (SEQ ID NO: 4). Particularly, the monomeric peptide unit comprises a core sequence of amino acids X; YX, CX, X; GPX, TWX, CX, X,, X;; (SEQ ID NO: 5), where X, can be R or H; X; canbe For M; X, canbe I, L, T, M,or V; X;is D or V;
X,can be G, XK, L, Q,R, S, or T; and X,, can be A, G, P, R, or Y. More particularly, the monomeric peptide unit of the dimer will comprise a core sequence of amino acids X,
YX, CX, X; GPX, TWX, CX, X,, X,, (SEQ ID NO: 6), where X, can be D, E, L, N, S,
T,orV; X,canbe A,H,K,L,M, S,or T; X,is Ror H; X; canbe K, R, S, or T; and X,, is
P.
Preferably, the monomeric peptide unit of the dimer will comprise a core sequence of amino acids X; YX, CX, X; GPX, TWX, CX, X;, X,, (SEQ ID NO: 6), where X, can be D,
E,L,N,S,T,orV; X, canbe A, HK, L,M, S,or T; X,is Ror H; X, canbe K, R, S, or T; and X,, is P.
Particularly preferred monomeric peptide units of the dimers include:
GGLYLCRFGPVTWDCGYKGG (SEQ ID NO:7);
GGTYSCHFGPLTWVCKPQGG (aka EMP-1) (SEQ ID NO:8); . 5 GGDYHCRMGPLTWVCKPLGG (SEQ ID NO:9);
VGNYMCHFGPITWVCRPGGG (SEQ ID NO:10);
GGVYACRMGPITWVCSPLGG (SEQ ID NO:11);
VGNYMAHMGPITWVCRPGG (SEQ ID NO:12);
GGTYSCHFGPLTWVCKPQ (aka EMP-16) (SEQ ID NO:13);
GGLYACHMGPMTWVCQPLRG (aka EMP-36) (SEQ ID NO:14);
TIAQYICYMGPETWECRPSPKA (aka EMP-38) (SEQ ID NO:15);
YSCHFGPLTWVCK (aka EMP-20 (SEQ ID NO:16);
YCHFGPLTWVC (aka EMP-23) (SEQ ID NO:17);
SCHFGPLTWVCK (aka EMP-24) (SEQ ID NO:18);
GGTASCHFGPLTWVCKPQGG (aka EMP-6) (SEQ ID NO:19);
GGTYSCHFAPLTWVCKPQGG (aka EMP-9) (SEQ ID NO:20);
GGTYSCFGPLTWVCKPQGG (aka EMP-27) (SEQ ID NO:21);
TYSCHFGPLTWVCKPQGG (aka EMP-17) (SEQ ID NO:22);
TYSCHFGPLTWVCKPQ (aka EMP-18) (SEQ ID NO:23),
YSCHFGPLTWVCKP (aka EMP-19) (SEQ ID NO:24);
YSCHFGPLTWVC (aka EMP-21) (SEQ ID NO:25);
YSCHFGALTWVCK (aka EMP-22) (SEQ ID NO:26);
GGCRIGPITWVCGG (aka EMP-25) (SEQ ID NO:27);
HFGPLTWV (aka EMP-26) (SEQ ID NO:28);
GGTTSCHFGPLTWVCKPQGG (aka EMP-7) (SEQ ID NO:29);
GGTFSCHFGPLTWVCKPQGG (aka EMP-8) (SEQ ID NO:30);
GGTYSCHFGALTWVCKPQGG (aka EMP-10) (SEQ ID NO:31);
GGTYSCHFGPATWVCKPQGG (aka EMP-11) (SEQ ID NO:32);
GGTYSCHFGPLAWVCKPQGG (aka EMP-12) (SEQ ID NO:33); } 30 GGTYSCHFGPLTAVCKPQGG (aka EMP-13) (SEQ ID NO:34);
GGTYSCHFGPLTFVCKPQGG (aka EMP-14) (SEQ ID NO:35);
GGTYSCHFGPLTWVCKAQGG (aka EMP-15) (SEQ ID NO:36);
GGTXSCHFGPLTWVCKPQGG (aka EMP-28, X = D-Tyr) (SEQ ID NO:37);
GGTXSCHFGPLTWVCKPQGG (aka EMP-29, X = p-NO.-Phe) : (SEQ ID NO:38);
GGTXSCHFGPLTWVCKPQGG (aka EMP-30, X = p-NH,-Phe) (SEQ ID NO:39);
GGTXSCHFGPLTWVCKPQGG (aka EMP-31, X = p-F-Phe) (SEQ ID NO:40);
GGTXSCHFGPLTWVCKPQGG (aka EMP-32, X = p-I-Phe) (SEQ ID NO:41);
GGTXSCHFGPLTWVCKPQGG (aka EMP-33, X = 3,5-dibromo-Tyr) (SEQ ID NO:42),
Ac-GGTYSCHFGPLTWVCKPQGG (aka EMP-34) (SEQ ID NO:43);
GGLYACHMGPMTWVCQPLGG (aka EMP-35) (SEQ ID NO:44);
LGRKYSCHFGPLTWVCQPAKKD (aka EMP-37) (SEQ ID NO:45); and
GGTYSEHFGPLTWVKKPQGG (aka EMP-39) (SEQ ID NO:46).
Most preferably, monomeric peptide units of the dimers include:
GGTYSCHFGPLTWVCKPQGG (aka EMP-1) (SEQ ID NO:8);
GGTASCHFGPLTWVCKPQGG (aka EMP-6) (SEQ ID NO:19);
GGTYSCHFAPLTWVCKPQGG (aka EMP-9) (SEQ ID NO:20); and
YCHFGPLTWVC (aka EMP-23) (SEQ ID NO:17).
EPO is administered by any suitable means as appropriate for the particular patient being treated, as would be apparent to one skilled in the art. The phrase “therapeutically effective” as used herein will vary from patient-to-patient, and depending on the particular range of biological activities possessed by the EPO molecule being administered. Typically, for EPO having hematopoietic activity, a therapeutically effective amount will be from about 1 to 500 1.U./kg body weight and more preferably from 50 to 300 LU./kg body weight especially when erythropoietin is administered via subcutaneously. For EPO molecules not possessing . hematopoietic activity the therapeutically effective dose may be more or less that an EPO molecule having hematopoietic activity. The preferred methods of administration are intravenous (iv) and subcutaneous (sc), with subcutaneous being generally preferred.
Hematopoietically active EPO is administered within the range of about 50 — 1000 U/kg per dose, one to five times per week. In another embodiment, the EPO composition is administrated directly to the nervous system. This administration route includes, but is not limited to, the intracerebral, intraventricular, intracerebroventricular, intrathecal, intracisternal, intraspinal and/or peri-spinal routes of administration, which can employ intracranial and intravertebral needles, and catheters with or without pump devices. Infusion doses can range, for example, . 5 from about 1.0 to 50,000 U/kg/min of EPO composition over a period ranging from several minutes to several days. Hematopoietically active EPO administration is delayed or withheld if the patient, male or female, exhibits a hemoglobin level in excess of about 15 g/dL.
The present invention provides in one embodiment a method to treat acute and chronic neurodegenerative disorders comprising administration of EPO or analogs thereof.
Acute neurodegenerative disorders include, but are not limited to, various types of acute neurodegenerative disorders associated with neuronal cell death or compromise including cerebrovascular insufficiency, focal or diffuse brain trauma, diffuse brain damage, and spinal cord injury. Examples of acute neurodegenerative disorders are: cerebral ischemia or infarction including embolic occlusion and thrombotic occlusion, reperfusion following acute ischemia, perinatal hypoxic-ischemic injury, cardiac arrest, as well as intracranial hemorrhage of any type (such as epidural, subdural, subarachnoid and intracerebral), and intracranial and intravertebral lesions (such as contusion, penetration, shear, compression and laceration), and whiplash shaken infant syndrome. Chronic neurodegenerative disorders that can be treated with one or more methods of the present invention include, but are not limited to, Alzheimer's disease, Pick's disease, diffuse Lewy body disease, progressive supranuclear palsy (Steel-Richardson syndrome), multisystem degeneration (Shy-Drager syndrome), chronic epileptic conditions associated with neurodegeneration, motor neuron diseases including amyotrophic lateral sclerosis, degenerative ataxias, cortical basal degeneration, ALS-Parkinson's-Dementia complex of Guam, subacute sclerosing panencephalitis,
Huntington's disease, Parkinson's disease, synucleinopathies (including multiple system atrophy), primary progressive aphasia, striatonigral degeneration, Machado-Joseph disease / spinocerebellar ataxia type 3 and olivopontocerebellar degenerations, Gilles De La Tourette's disease, bulbar and pseudobulbar palsy, spinal and spinobulbar muscular atrophy (Kennedy's } 30 disease), primary lateral sclerosis, familial spastic paraplegia, Werdnig-Hoffmann disease,
Kugelberg-Welander disease, Tay-Sach's disease, Sandhoff disease, familial spastic disease,
Wohlfart-Kugelberg-Welander disease, spastic paraparesis, progressive multifocal leukoencephalopathy, familial dysautonomia (Riley-Day syndrome), and prion diseases (including, but not limited to Creutzfeldt-Jakob, Gerstmann-Striussler-Scheinker disease, ) Kuru and fatal familial insomnia).
Because of the combination of neuroprotection and neurite outgrowth induced by thEPO, other clinical conditions can be treated with one or more methods of the present invention include treating and / or preventing the neurological (including, but not limited to, cognitive) and psychiatric (including, but not limited to, psychopathology, depression, or anxiety), manifestations associated with peripheral diseases including, but not limited to,
EPO deficiency (e.g., renal disease), blood loss of any kind (including, but not limited to, hemodialysis, peritoneal dialysis, diagnostic sampling, occult gastrointestinal bleeding), renal failure and end-stage renal disease, renal transplantation, and other conditions associated with anemia and neurological and neuropsychiatric manifestations, including, but not limited to, hematological and non-hematological malignancies / cancer, symptoms or complications in patients receiving chemotherapy (including, but not limited to, cisplatin) and other drugs (including, but not limited to, zidovudine), other hematological disorders (including, but not limited to, sickle cell anemia and thalassemia), inflammatory and infectious disorders (including, but not limited to, human immunodeficiency viral infections), chronic systemic autoimmune diseases (including, but not limited to, systemic lupus erythematosus), Henoch Schonlein Purpura, and hemolytic uremic syndrome. Also included in the present invention are the treatment and / or prevention of neurological and neuropsychiatric manifestations resulting from chemical, toxic, infectious and radiation injury of the nervous system and as a result of prematurity, as well as the treatment and / or prevention of neurological and neuropsychiatric consequences of encephalopathies including, but not limited to, those of anoxic-ischemia, hepatic, glycemic, uremic, electrolyte and endocrine origin.
Also, because of the combination of neuroprotection and neurite outgrowth induced ? by rhEPO, this molecule can also be applicable for the treatment and / or prevention of plexopathies (including plexus palsies), multifocal neuropathies, sensory neuropathies, motor neuropathies, sensory-motor neuropathies, infections neuropathies, autonomic neuropathies, sensory-autonomic neuropathies, demyelinating neuropathies (including, but not limited to,
Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy),
other inflammatory and immune neuropathies, neuropathies induced by drugs, neuropathies induced by pharmacological treatments, neuropathies induced by toxins, traumatic neuropathies (including, but not limited to, compression, crush, laceration and segmentation neuropathies), metabolic neuropathies, endocrine and paraneoplastic neuropathies, and other . 5 neuropathies such as Charcot-Marie-Tooth disease (type 1a, 1b, 2, 4a,1-X linked),
Friedreich's ataxia, metachromatic leukodystrophy, Refsum's disease, adrenomyeloneuropathy, Ataxia-telangiectasia, Déjerine-Sottas neuropathy (types A and B),
Lambert-Eaton syndrome, and disorders of the cranial nerves.
The following examples illustrate the present invention without, however, limiting the same thereto.
EXAMPLE 1 rhEPO is expressed in primary rat neuronal cultures and in neuronal cell lines
Primary Neuronal Cell Culture
Dissociated hippocampal and cortical cell cultures were established from embryonic day 18 rat fetuses as previously described (Mattson et al., 1994). Briefly, fetuses were removed via cesarean section from pregnant moms (Sprague-Dawley) anesthetized with halothane according to the AVMA Panel on Euthanasia. Pups were decapitated and the - brains were removed and placed in HEPES-buffered Hank’s Balanced Salt solution (HBSS;
Gibco). The hippocampi and cortices were dissected out and pooled according to tissue-type.
Tissue was trypsinized for 15 min (lmg/ml trypsin-HBSS; Worthington), rinsed with fresh
HBSS, incubated in trypsin inhibitor (1mg/ml; Sigma) for 5 min, rinsed again with fresh
HBSS and then triturated in Iml fresh HBSS with a fire-polished glass pipette. Dissociated cells were seeded at. 30,000 cells/well onto poly-D-lysine coated 96-well plates (Collaborative BioScience). Each well contained 100ul of Eagle’s Minimal Essential Media (MEM; Gibco) supplemented with 26mM NaHCO; (Sigma), 56mM glucose (Sigma), 15 mM
KCl (Sigma), 1mM sodium pyruvate (Sigma), 1.1mM L-glutamine (Sigma), 10% (v/v) heat- inactivated fetal bovine serum (Hyclone), and 0.001% gentamicin sulfate (Sigma) (pH 7.4).
Cells were allowed to attach for 24h in a humidified 37°C 5% CO, incubator before experimental treatment. The culture media was aspirated and exchanged with fresh media every three days.
Immunocytochemistry
Parallel hippocampal and cortical cultures were treated as described above and : were processed for immunocytochemistry (ICC) as described previously (Smith-
Swintosky et al., 1997). Briefly, cells were plated onto four-chamber poly-D-lysine ’ 5 coated glass slides (LabTek, Napersville, IL). On the seventh day in culture, the culture media was removed and the cells were washed once with Dulbecco’s phosphate buffered saline (DPBS; Sigma) and then fixed with 10% phosphate-buffered formalin for 15min at room temperature. After fixation, the cultures were rinsed with DPBS and placed in blocking serum for 10min (normal horse serum; 1:50 dilution in DPBS; Vector Labs,
Burlingame, CA). Cultures were rinsed again and then incubated for 30min in an anti- mouse monoclonal antibody specific to the EPO receptor (EBP-7); 1:75 dilution in antibody diluent (Zymed, South San Francisco, CA). Cultures were rinsed several times with DPBS, then exposed to biotinylated secondary antibody for 30min (Vector Labs).
Cultures were rinsed a final time and then incubated for 30min in avidin-biotinylated horseradish peroxidase complex (mouse IgG ABC kit, Vector Labs). The presence of the primary antibody was detected using 3’°3-diaminobenzidine tetrahydrochloride (DAB,
Biomeda, Foster City, CA) - two exposures for Smin each. Cells were then counterstained with hematoxylin, dehydrated, cleared, coverslipped and photographed under an Olympus BX-2 light microscope.
Results
Robust staining for EPO receptor was observed in both neurons and glia within hippocampal and cortical cultures (Figure la and Figure 1b). EPO receptor expression levels appear to increase with time in culture.
Discussion
These results show that EPO plays a role in early development of the nervous system, : particularly the hippocampus and cerebral cortex. Lmmunohistochemistry of neuronal cell lines
The neuronal cell lines PC-12, derived from a pheochromocytoma of the rat adrenal gland (Greene and Tischler, 1976), and SK-N-MC, obtained from a neuroepithelioma of a brain of human origin (Spengler et al., 1973), were used. PC-12 cells can be reversibly induced to the neuronal phenotype in the presence of nerve growth factor (NGF). PC-12 cells were grown on poly-D-Lysine coated tissue culture dishes in DMEM containing 10% horse serum and 5% FBS and in the presence of 0.1 pg/ml NGF for 7 days to induce the neuronal ) 5 phenotype. SK-N-MC cells were cultured in minimal essential media supplemented with 1.0 mM Sodium pyruvate, 1.5 g/L sodium bicarbonate, 2mM glutamine and 10% FBS for 4 days.
PC-12 and SK-N-MC cells were cultured in a 96 well plate from Greiner, conducive for microscopy. On the day of the experiment cells were fixed in 10% Formalin containing 10% sucrose and incubated in blocking buffer (40 mM Tris HCL, Ph 8.0, 27mM NaCl, and 0.2%Tween 20). Receptors for erythropoietin were detected by incubating the cells with a rabbit polyclonal, anti-erythropoietin receptor antibody (C-20 from Santa Cruz) and a FITC conjugated secondary antibody. Labeled cells were visualized using a fluorescent microscope (ATTO).
Results
A polyclonal antibody against the erythropoietin receptor labeled both SK-N-MC and
PC-12 cells as seen in Figure 2 (right panels). All SK-N-MC cells visible at low magnification appeared to be labeled with the antibody. The majority of PC-12 cells that were detectable were labeled with the anti-erythropoietin receptor antibody. A few intact PC- 12 cells that retained a characteristic neuronal phenotype in this preparation showed staining throughout the axonal process as well as in the cell body. Secondary antibody alone did not label either cell type (Figure 2, left panels).
Therefore, these results demonstrate that these cell lines, SK-N-MC cells from a human neuroepithelioma and PC-12 cells from a rat pheochromocytoma, express the erythropoietin receptor. These cell lines are therefore responsive to erythropoietin and can provide a good system to study the effects of erythropoietin on neurons. . 30
EXAMPLE 2
EPQ induced gene expression in PC12 cells
Cell Culture
PC-12 cells (from a rat Pheochromocytoma) were cultured on poly-D-Lysine coated tissue culture plastic in DMEM containing 10 % FBS and 5% Horse serum. To induce the neuronal phenotype in PC-12 cells, serum was removed and the cells were treated with NGF (50 ng/ml). Cells were grown for 7 days in the presence of the NGF then used for experiments.
EPO Treatment and RNA isolation
PC-12 cells were cultured as described in Example 1 in a 10 cm poly-D-lysine coated tissue culture dish. Cells were incubated in the presence of 1U/ml of EPO for 24 hr. Total
RNA was then isolated using a Qiagen RNAeasy mini prep kit and used for RT-PCR.
Quantitative RT-PCR
Real time reverse transcription and PCR were performed in a single reaction using a light cycler and an RNA amplification kit from Roche Molecular Biochemicals. RNA was quantitated and added in equal amounts to reaction mix that includes the dsDNA specific dye
SYBR green I. Specific PCR reaction products are quantitated by detecting the amount of fluorescence in the reaction at each PCR cycle. Final analysis was performed using the data analysis software included with the light cycler instrument.
Pre-treatment of PC-12 cells with EPO (1U/ml) for 24 hr resulted in significant changes in the gene expression of the bcl-2 family members bcly, and bak as seen in Figure 3. Cells treated with EPO showed a 6-fold increase in the expression of the anti-apoptotic gene, bel, and a S-fold decrease in the expression of the pro-apoptotic gene, bak. EPO has been shown previously to increase the survival of red blood cell progenitor cells by increasing bcly; expression (Silva et al., 1996). These results show that EPO uses a similar mechanism to protect neurons from undergoing apoptosis in response to injury. The regulation of bak shows that EPO can effect the expression of additional genes to elicit this effect.
EXAMPLE 3 } 5 rhEPQ neuroprotection and neurite outgrowth effects on rat hippocampal and cortical cells and PC12 cells
Primary Neuronal Cell Culture
Dissociated hippocampal and cortical cell cultures were established from embryonic day 18 rat fetuses as previously described (Mattson et al., 1994). Briefly, fetuses were removed via cesarean section from pregnant moms (Sprague-Dawley) anesthetized with halothane according to the AVMA Panel on Euthanasia. Pups were decapitated and the brains were removed and placed in HEPES-buffered Hank’s Balanced Salt solution (HBSS;
Gibco). The hippocampi and cortices were dissected out and pooled according to tissue-type.
Tissue was trypsinized for 15 min (Img/ml trypsin-HBSS; Worthington), rinsed with fresh
HBSS, incubated in trypsin inhibitor (1mg/ml; Sigma) for 5 min, rinsed again with fresh
HBSS and then triturated in 1ml fresh HBSS with a fire-polished glass pipette. Dissociated cells were seeded at 30,000 cells/well onto poly-D-lysine coated 96-well plates (Collaborative BioScience). Each well contained 100ul of Eagle’s Minimal Essential Media (MEM; Gibco) supplemented with 26mM NaHCO, (Sigma), S6mM glucose (Sigma), 15mM
KCl (Sigma), ImM sodium pyruvate (Sigma), 1.1mM L-glutamine (Sigma), 10% (v/v) heat- inactivated fetal bovine serum (Hyclone), and 0.001% gentamicin sulfate (Sigma) (pH 7.4).
Cells were allowed to attach for 24h in a humidified 37°C 5% CO, incubator before experimental treatment. The culture media was aspirated and exchanged with fresh media every three days.
Glutamate Toxicity Assay
Cortical cells were seeded at 200,000 cells/dish onto polyethylenimine-coated 35mm culture dishes. Each dish contained 1.5ml MEM supplemented as described above. On the } 30 seventh day in culture, four fields per pre-marked dish were visualized with a Nikon Diaphot inverted microscope (10x magnification) and photographed prior to experimental treatment.
Immediately following, the cultures were treated with vehicle or recombinant human erythropoietin (rhEPO; lot #41C514; 50uM stock in 0.2M citrate, 0.585g.L NaCl diluted to appropriate concentrations in Dulbecco’s phosphate buffered saline (DPBS; Sigma) + 0.1% bovine serum albumin (BSA; Sigma)). Twenty-four hours later the cultures were treated with 100puM glutamate (Sigma). Twenty-four hours post-glutamate, the four fields from each dish were photographed again. Cell survival was measured by counting viable cells in each field pre- and post-experimental treatment. Neurons were considered viable if they had neurites that were uniform in diameter and smooth in appearance, and somata that were smooth and round to oval in shape. Data were expressed as percent of control (vehicle; mean + SD).
PC12 Cell Culture
PC-12 cells (from a rat Pheochromocytoma) were cultured on poly-D-Lysine coated tissue culture plastic in DMEM containing 10 % FBS and 5% Horse serum. To induce the neuronal phenotype in PC-12 cells, serum was removed and the cells were treated with NGF (50 ng/ml). Cells were grown for 7 days in the presence of the NGF then used for experiments.
Glutamate Toxicity
PC-12 cells were cultured as described above. 24 hr prior to insult, cells were treated with thEPO at concentrations ranging from 1 pm to 1 nm. On the day of the experiment, cells were exposed to 200 uM glutamate for 30 min. Cells were then washed 2 times with fresh media to remove the glutamate and cultured in fresh media containing NGF but no EPO.
After 24 hr cells were assayed for viability using a trypan blue exclusion assay. Briefly, media was removed and the cells were incubated in 0.4% Trypan Blue for 5 min. Cells were then washed gently with PBS, then fixed with 10% formalin. Cell viability was determined by counting the total number of cells vs. the number of trypan blue positive (dead) cells.
NGF withdrawal
PC-12 cells were cultured as described above in a 96 well poly-d-lysine coated multi-well plate and treated with rthEPO (1 pm to 10 nm) for 24 hr prior to NGF withdrawal. On the day of the experiment the cells were washed with buffer 3 times to remove NGF and then cultured in fresh media without NGF. Immediately following
NGF washout cells were counted (t=0) to determine the number of living cells. Cell viability was based on morphological characteristics including phase brightness, presence of axons, and absence of blebbing. Cell counts were performed at 12 hr, 24 hr, 48 hr and . 5 72 hr and the number of viable cells were scored.
Neurite Outgrowth Assay
Twenty-four hours after plating, cultures were treated with vehicle (PBS+0.1% BSA), 100ng of various growth factors (brain derived neurotrophic factor (BDNF; Promega), glial- derived neurotrophic factor (GDNF; Promega), nerve growth factor (NGF; Boehringer
Mannheim), basic fibroblast growth factor (bFGF; Boehringer Mannheim), insulin-like growth factor —1 (IGF-1; Boehringer Mannheim), neurotrophin-3 (NT3; Calbiochem), neurotrophin-4 (NT4; Calbiochem), ciliary neurotrophic factor (CNTF; Calbiochem), epidermal growth factor (EGF; Calbiochem), vascular endothelial growth factor (VEGF; Calbiochem)), or thEPO (prepared same as above; 10fM — 10nM)). Each treatment condition was run in quadruplicate or octuplicate. On the third day in culture, the media was aspirated off and replaced with fresh media and test compound. At one week in culture, the cells were fixed with 10% phosphate-buffered formalin for 15min, then rinsed with DPBS (Sigma) and placed in blocking serum for 30 min (horse serum; 1:50 dilution in DPBS; Vector Labs).
Cultures were rinsed again with DPBS and then incubated in primary antibody for 2 hr (microtubule-associated protein-2 (MAP-2) is a selective marker for dendritic processes; anti-mouse monoclonal (Chemicon); 1:1000 dilution of MAP-2 in antibody diluent (Zymed)). Negative control wells were incubated in antibody diluent alone. Background signal was determined by blank wells (cell-free) incubated with or without antibody.
Cultures were rinsed again with DPBS and then placed in fluorescein for 1 hr (FITC; anti- mouse IgG; rat adsorbed; 1:50 dilution in DPBS; Vector Labs). Cultures were rinsed a final time with DPBS and then the plates were read on a Cytofluor 4000 fluorescence plate reader.
Neurite outgrowth was expressed as percent change from control (vehicle; mean fluorescence + SD). } 30
Results
Neuroprotection study with primary neuronal cultures: Pretreatment of cultures with thEPO for 24h prior to glutamate administration resulted in a significant increase in neuronal survival (Figure 4). Cell survival was maximally increased approximately 200% over ) 5S parallel cultures treated with glutamate alone. The neuroprotective effect of thEPO was concentration-dependent, with the greatest effects observed at pM concentrations in which cell survival was greater than or equal to vehicle (no glutamate) treated cultures.
Neuroprotection study with PC12 cells: Pre-treatment with EPO resulted in a significant decrease in cell death induced by both glutamate toxicity and growth factor withdrawal in PC-12 cells (Figures 5 and 6). The peak concentration for the neuroprotective effect in both experiments was 10 pm. The dose response curve for the neuroprotective effect of EPO was bi-phasic with the ability of EPO to protect cells against cytotoxicity decreasing at concentrations above 10 pm, with no significant effect at 1 nm. These results suggest that
EPO is able to prevent an apoptotic response in neurons exposed to a variety of cytotoxic insults
Neurite outgrowth study with primary neuronal cultures: Cultures treated with thEPO resulted in a significant increase in neurite outgrowth as measured by MAP2-FITC immunofluorescence. The neurite outgrowth promoting effect was concentration dependent with maximal activity observed at pM levels (Figures 7 and 8). The results indicate that rhEPO treatment induced a larger outgrowth response in the hippocampal cultures (12-44% over control) than in the cortical cultures (15-29% over control). A comparison between rhEPO and known growth factors indicates that they exhibit regional differences in their neurite outgrowth promoting abilities. rhEPO’s ability to increase neurite outgrowth in cortical cultures is greater than or equal to that of known growth factors. This observation is compelling and important since few factors have such effects on cortical cells. On the other : hand, many growth factors exert strong outgrowth responses in the hippocampus (38-86% over control). Compared to such growth factors, thEPO showed moderate yet robust ’ 30 outgrowth promoting activity; however, its activity was superior to several growth factors including BDNF, NGF and VEGF.
Discussion
The neuroprotection studies confirmed previous evidence that rhEPO is protective at pM concentrations against glutamate toxicity and serum withdrawal in vitro. ] 5 Surprisingly we discovered that thEPO promotes neurite outgrowth in primary mammalian neural cells. The effect was robust for hippocampal and cortical cells. The effect was potent with efficacy observed at sub-picomolar concentrations, far more potent than any previous EPO related observation. Moreover, in cerebral cortical neurons, which respond to few growth factors, thEPO was superior in inducing neurite outgrowth relative to the majority of known growth factors.
From a therapeutic perspective, the observation that thEPO promotes neuroprotection and neurite outgrowth in cerebral cortical neurons is very important. During neurodegeneration, neural cells can be in different stages of the process. Some may be stressed, others experience significant neurite retraction and loss of synaptic input, and eventually all affected cells will succumb to death. A therapeutic agent that can intervene in this process at multiple levels can be of great benefit to the recovery of the neural cells and eventually neural function. The present data support that thEPO accomplishes this task by protecting the cells, by enhancing their survival, by promoting re-establishment of synaptic contacts and connections, and by stabilizing the neuronal and neural circuitry.
It should also be specified that the data are particularly important, considering that very few growth factors are effective in cerebral cortical neurons, and also that very few growth factors display the dual activity as neuroprotectants and promoters of neurite outgrowth in cortical neurons. It is particularly relevant that this dual activity of thEPO was observed at sub-picomolar / picomolar concentrations.
EXAMPLE 4
EPO MIMETIC PEPTIDES STIMULATE NEURITE OUTGROWTH
Cell Culture
Dissociated hippocampal and cortical cell cultures were established from embryonic - day 18 rat fetuses as previously described (Mattson et al., 1994). Briefly, fetuses were removed via cesarean section from pregnant moms (Sprague-Dawley) anesthetized with ’ 5 halothane according to the AVMA Panel on Euthanasia. Pups were decapitated and the brains were removed and placed in HEPES-buffered Hank’s Balanced Salt solution (HBSS;
Gibco). The hippocampi and cortices were dissected out and pooled according to tissue-type.
Tissue was trypsinized for 15 min (1mg/ml trypsin-HBSS; Worthington), rinsed with fresh
HBSS, incubated in trypsin inhibitor (1mg/ml; Sigma) for 5 min, rinsed again with fresh
HBSS and then triturated in 1ml fresh HBSS with a fire-polished glass pipette. Dissociated cells were seeded at 30,000 cells/well onto poly-D-lysine coated 96-well plates (Collaborative BioScience). Each well contained 100ul of Eagle’s Minimal Essential Media (MEM; Gibco) supplemented with 26mM NaHCO, (Sigma), 56mM glucose (Sigma), 15mM
KCl (Sigma), ImM sodium pyruvate (Sigma), 1.1mM L-glutamine (Sigma), 10% (v/v) heat- inactivated fetal bovine serum (Hyclone), and 0.001% gentamicin sulfate (Sigma) (pH 7.4).
Cells were allowed to attach for 24h in a humidified 37°C 5% CO, incubator before experimental treatment. The culture media was aspirated and exchanged with fresh media every 3 days. :
Neurite Outgrowth Assay
Twenty-four hours after plating, cultures were treated with vehicle (PBS+0.1% BSA), 100ng of various growth factors (brain derived neurotrophic factor (BDNF; Promega), glial- derived neurotrophic factor (GDNF; Promega), nerve growth factor (NGF; Boehringer
Mannheim), basic fibroblast growth factor (bFGF; Boehringer Mannheim), insulin-like growth factor —1 (IGF-1; Boehringer Mannheim), neurotrophin-3 (NT3; Calbiochem), neurotrophin-4 (NT4; Calbiochem), ciliary neurotrophic factor (CNTF; Calbiochem), epidermal growth factor (EGF; Calbiochem), vascular endothelial growth factor (VEGF; . Calbiochem)), or Epo mimetic peptides (EMP1, EMP6, EMP9, EMP23 and EMP27; diluted in DPBS+0.1% BSA; 10fM — 10nM; Table 1). Each treatment condition was run in ) 30 quadruplicate. On the third day in culture, the media was aspirated off and replaced with fresh media and test compound. At one week in culture, the cells were fixed with 10%
phosphate-buffered formalin for 15min, then rinsed with DPBS (Sigma) and placed in blocking serum for 30 min (horse serum; 1:50 dilution in DPBS; Vector Labs). Cultures were rinsed again with DPBS and then incubated in primary antibody for 2 hr (microtubule- associated protein-2 (MAP-2) is a selective marker for dendritic processes; anti-mouse , 5 monoclonal (Chemicon); 1:1000 dilution of MAP-2 in antibody diluent (Zymed)). Negative control wells were incubated in antibody diluent alone. Background signal was determined by blank wells (cell-free) incubated with or without antibody. Cultures were rinsed again with DPBS and then placed in fluorescein for 1 hr (FITC; anti-mouse IgG; rat adsorbed; 1:50 dilution in DPBS; Vector Labs). Cultures were rinsed a final time with DPBS and then the plates were read on a Cytofluor 4000 fluorescence plate reader. Neurite outgrowth was expressed as percent change from control (vehicle; mean fluorescence + SEM).
Results
Neurite outgrowth study: Cultures treated with EMP’s resulted in a significant increase in neurite outgrowth as measured by MAP2-FITC immunofluorescence. The neurite outgrowth promoting effect was concentration dependent with maximal activity observed at pM levels (Figures 9-18). The results indicate that EMP’s displayed different activity profiles. At the concentrations tested, EMP-1 and 6 displayed typical bell-shaped dose- response profiles in hippocampal cultures with peak activity observed between 30-300pM ] (83-117% increase over vehicle). EMP-9 and 27 exhibited a flat response profile in hippocampal cultures with peak activity observed at similar concentrations as EMP-1 and 6, . but the amplitude of the response was greatly attenuated (29-32% increase over vehicle).
EMP-23 had a modest response to EPO in hippocampal cultures with peak activity observed between 30pM-1nM that led to a 43-46% increase over vehicle response. In the cortical cultures, EMP-1, 9 and 27 exhibited response profiles similar to most known growth factors — a flat response overall with maximal activity occurring between 30-300pM reaching 32-40% above the vehicle response. EMP-6 and 23 displayed typical bell-shaped dose-response profiles with peak activity observed between 30-300pM resulting in a 68-87% increase in outgrowth over vehicle response levels. Overall, EMP-6 promoted robust neurite outgrowth activity in both hippocampal and cortical cultures; whereas, EMP-1 showed selective effects in hippocampal cultures over cortical cultures and EMP-23 effects were greater in cortical cultures than hippocampal cells. EMP-9 and 27 neurite outgrowth responses were less impressive overall.
A comparison between the EMP’s and known growth factors indicated that they exhibit regional differences in their neurite outgrowth promoting abilities. The EMP’s ability to increase neurite outgrowth in cortical cultures was greater than or equal to that of known growth factors (Figure 9-18). This observation is compelling and important since few factors have such effects on cortical cells. On the other hand, many growth factors exert strong outgrowth responses in the hippocampus (38-86% over control). Compared to such growth factors, the EMP’s showed moderate yet robust outgrowth promoting activity; however, they displayed superior activity over BDNF, NGF and VEGF.
Discussion
EMP’s promote neurite outgrowth in mammalian cells. The effect was robust for hippocampal and cortical cells. The neurite outgrowth promoting effect was superior to that of various growth factors. The effect was potent with efficacy observed at picomolar concentrations. :
It should also be specified that the data are particularly important, considering that very few growth factors or mimetics are effective in cerebral cortical neurons in promoting : neurite outgrowth. It is particularly relevant that this activity of the EMPs was observed at . sub-picomolar / picomolar concentrations. "30
EXAMPLE 5
EPO protects against ischemic injury
Subjects ; 5 Male spontaneous hypertensive rats (Charles River) weighing between 250-300g were weighed and then anesthetized with ketamine (100mg/ml)/xylazine (20mg/ml) cocktail (1.2ml/kg; i.p.). The level of anesthetic was assessed by corneal reflex (air puff to eye) and leg jerk in response to tail or foot pinch. Once the rat was anesthetized, it was placed on a small animal surgical board and restrained during the surgical procedure. The rat’s body temperature was monitored continuously with a rectal probe and maintained at 37°C with a homeostatic heating pad.
Experimental model of cerebral ischemia
Rats were rendered ischemic by tandem occlusion of the left common carotid artery and the left middle cerebral artery for 2h followed by 22h of reperfusion using a modification of the technique described by Brint and co-workers (J. Cereb Blood Flow Metab 8:474-485, 1988). Specifically, the left CCA was isolated through an incision in the ventral surface of the neck. For isolation of the ipsilateral MCA, a second incision was made between the lateral canthus of the left eye and the corresponding external auditory canal to bare the underlying skull. The MCA was exposed through a 5mm burrhole drilled 2-3mm rostral to the fusion of the zygomatic arch and the squamosal bone under direct visualization with a
Zeiss operating microscope. The dura was opened with a sterile 26g needle and a platinum alloy wire (0.1mm diameter) was inserted beneath the MCA just superior to the inferior cortical vein. The MCA was temporarily occluded by elevation and compression of the vessel across the alloy wire, as described by Aronowski and colleagues (Stroke, 25:2235-2240, 1994). Concurrently, the CCA was occluded with an aneurysm clip. The duration of occlusion of the CCA and the MCA was 2h. At the end of this period, the wire and the clip were carefully removed to allow reperfusion of the vessels and the incision area was sutured shut. The rat was placed in an isolation cage to recover before returning to his home cage. .
Study Design
Study I: EPO and vehicle delivered via osmotic mini-pump : Twenty-hours prior to the onset of ischemia, an osmotic mini-pump (Model 1003D;
Alza) filled with vehicle or EPO was placed between the scapula of the rat. A catheter attached to the pump was inserted and tethered within the right jugular vein for continuous infusion of drug at a rate of 1pl/hr. Rats were divided into five groups: (1) sham-operated vehicle-treated, (2) ischemic vehicle treated, (3) ischemic 1.32U/day EPO treated, (4) ischemic 132U/day EPO treated and (5) ischemic 1321U/day EPO treated. On Day Two, rats were rendered ischemic as described above. Twenty-two hours later, the rats were evaluated for behavioral performance, a blood sample was collected for terminal plasma levels of EPO and then the rat was euthanized, brain removed, sectioned and stained for histological analysis.
Study II: EPO and vehicle delivered as a single intravenous bolus injection
On Day One, the rats were rendered ischemic as described above. Rats were divided into four groups: (1) ischemic vehicle treated, (2) ischemic 1000U/kg EPO treated, (3) ischemic 2500U/kg EPO treated and (4) 5000U/kg EPO treated. Fifteen minutes post-occlusion, the rats received vehicle or EPO as an intravenous bolus injection.
Twenty-two hours later, the rats were evaluated for behavioral performance, a blood sample was collected for terminal plasma levels of EPO and then the rat was euthanized, brain removed, sectioned and stained for histological analysis.
Study III: EPO and vehicle delivered as repeat intravenous bolus injections
On Day One, the rats were rendered ischemic as described above. Rats were divided into two groups: (1) ischemic vehicle treated and (2) ischemic 2500U/kg EPO treated.
Drug was administered as an intravenous bolus at 15min, 2h, 4h and 6h post- occlusion for a total dose of 10,000U/kg. Twenty-two hours later, the rats were ) evaluated for behavioral performance, a blood sample was collected for terminal plasma levels of EPO and then the rat was euthanized, brain removed, sectioned and
C30 stained for histological analysis.
Outcome measures
Plasma Determinations: Blood samples were collected from each rat via the orbital sinus at the time of sacrifice. Plasma was separated out, frozen and analyzed by EPO ELISA for determination of plasma concentration (U/ml). . 5
Infarct Volume: Brains were removed, blocked into Imm slabs and stained with 2,3,5-triphenyl tetrazolium chloride dye (TTC; Sigma) for 15 min at room temperature.
Stained sections were stored in 10% buffered formalin at 40C. Sections were visualized by a
Nikon SMZ-U microdissecting scope. Images of each brain section were captured with a
CCD camera and processed using Image Pro Phase III software in order to calculate infarct volume.
Results
Study I: EPO given at 132 or 1321U/day as a continuous infusion via osmotic mini- pump significantly reduced infarct volume (Figure 19). Plasma concentrations correlated with the protective effect (Figure 20).
Study I: EPO given as a single iv bolus 15 min post-occlusion did not protect against ischemic damage in this model at 1000, 2500 or 5000U’kg (Figure 21). Plasma concentrations were low in each group (Figure 22).
Study III: EPO given as a repeat iv bolus of 2500U/kg at 15min, 2h, 4h and 6h post- occlusion led to a significant decrease in infarct volume (Figure 23). Plasma concentrations are presently being determined (Figure 24).
Discussion
Data support that continuous or repeat dosing with low to moderate concentrations of
EPO can significantly reduce infarct volume in spontaneous hypertensive rats rendered ischemic via the transient tandem occlusion of the CCA and MCA. The results also support ) that there is a critical relationship between the amount and timing of EPO administration for } 30 the protective effect to occur. Low doses of EPO given over an extended period of time can be more beneficial than high doses given the same way or as a single bolus infusion. This is in agreement with the in vitro data indicating that EPO maximal protective effect is observed at low doses (pM) and actually looses efficacy at higher doses (UM).
Johnson, D.L., Farrell, F.X., Barbone, F.P., McMahon, F.J., Tullai, J., Hoey K., Wrighton, } N.C., Livnah, O., Middleton, S.A., Loughney, D., Stura, E.A., Dower, W.J., Mulcahy, L.S., } 5 Wilson, L.A. & Jolliffe L.K., Identification of a 13 Amino Acid Peptide Mimetic of
Erythropoietin and Description of Amino Acids Critical for the Mimetic Activity of EMP1,
Biochemistry 37, 3699-3710 (1998).
Johnson, D.L., Farrell, F.X., Barbone, F.P., McMahon, F.P., Tullai, J., Kroon, D., Freedy, J., Zivin , R.A.,, Mulcahy, L.S., & Jolliffe, LK. Amino Terminal Dimerization of an
Erythropoietin Mimetic Peptide Results in Increased Erythropoietic Activity, Chemistry &
Biology 4, 939-950 (1997).
Johnson, Dana L.; Zivin, Robert A. Agonist peptide dimers. US Patent No. 5,767,078
Campana, W.M., Misasi, R. and O’Brien, J.S. (1998) Identification of a neurotrophic sequence of erythropoietin. Inter. J. Mol. Med. 1:235-241.
Patent application WO 95/03821, O’Brien, 1.S., Kishimoto, Y. and Altman, D.E. Title: Prosaposin and cytokine-derived peptides as therapeutic agents.
Sadamoto, Y, Igase, K, Sakanaka, M., Sato, K, Otsuka, H., Sakaki, S., Masuda, S. and
Sasaki, R. (1998). Erythropoietin prevent place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery. Biochem Biophys Res
Comm. 253:26-32.
Tabira, T., Konishi, Y. and Gallyas, F. (1995). Neurotrophic effect of hematopoietic cytokines on cholinergic and other neurons in vitro. Int. J. Dev. Neurosci. 13:241-252.
Morishita, E., Masuda, S., Nagao, M., Yasuda, Y. and Sasaki, R. (1997). Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevent in vitro giutamate-induced neuronal death. Neurosci 76:105-116.
Sakanaka, M, Wen T-C, Matsuda, S, Masuda, S., Morishita, E., Nagao, M., and Sasaki, R. - (1998) In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc.
Natl. Acad. Sci. 95:4635-4640. rd 5
Marti, H.H., Gassman, M., Wenger, R.H., Kvietikova, I., Morganti-Kossmann, M.C.,
Kossmann, T., Trentz, O., and Bauer, C. (1997) Detection of erythropoietin in human liquor: Intrisic erythropoietin production in the brain. Kidney Int. 51:416-418. 10 . Konishi, Y., Chui, D-H, Hirose, H., Kunishita, T. and Tabira, T. (1993) Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons in vitro and in vivo. Brain Res. 609:29-35.
Bernaudin, M., Marti, H.H., Roussel, S., Divoux, D., Nouvelot, A., MacKenzie, E.T. and
Petit, E. (1999). A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J. Cereb. Blood Flow Metab. 19:643-51.
Nakamura, T., Ebihara, 1., Shimada, N. and Koide, H. (1998) Elevated levels of erythropoietin in cerbrospinal fluid of depressed patients. Amer. J Med Sci 315:199-201.
Masuda, S., Okano, M., Yamagishi, K., Nagao, M., Ueda, M. and Sasaki, R. (1994) A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. J.
Biol. Chem. 269:19488-93.
Patent application WO 98-CA991, Weiss, S and Sorokan, S.T. Title: Erythropoietin- mediated neurogenesis. . Campana, W.M., Misasi, R. and O’Brien, J.S. (1998) Identification of a neurotrophic sequence of erythropoietin. Inter. J. Mol. Med. 1:235-241.
C30
Patent application: WO 95/03821, O’Brien, J.S., Kishimoto, Y. and Altman, D.E. Title:
Prosaposin and cytokine-derived peptides as therapeutic agents.
Konishi, Y., Chui, D-H, Hirose, H., Kunishita, T. and Tabira, T. (1993) Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons in vitro and in ’ vivo. Brain Res. 609:29-35, ] 5
Mattson, M.P., Barger, S.W., Begley, J, and Mark, R.J. (1994) Calcium, free radicals and excitotoxic neuronal death in primary cell culture. Methods Cell Biol. 46:187-216.
Smith-Swintosky VL, Cheo-Isaacs CT, D’Andrea MR, Santulli RJ, Darrow, AL, Andrade-
Gordon P. (1997) Protease-activated receptor 2 (PAR-2) is present in the rat hippocampus and is associated with neurodegeneration. J. Neurochem., 69:1890-1896.
Silva, M., Grillot, D., Benito, A., Richard, C., Nunez, G., Fernandez-Luna, J.L. (1996).
Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through
Bcl-y and Bel-2. Blood 88, pp1576-1582.
Claims (84)
1. Use of a peptide comprising one or more monomeric peptides of 8 to about 40 amino acids in length that bind to EPO receptor, each monomeric peptide comprising a sequence of amino acids XXX, X XX X 4X7 (SEQ ID NO: 47), wherein X,is Gor A; Xp, is Por A;
X. is Tor A; X, is selected from W, A, and F; : X, is selected from R, H, Y, L, and W, or X, is nonexistent; Xs is selected from F, M, and I; Xg is independently selected from the 20 genetically coded L-amino acids or the stereoisomeric D-amino acids; and Xj; is selected from D, V, E, I, and L, in the manufacture of a preparation for treating a subject having a condition mediated by neurotoxicity, neurodegeneration or neurological damage.
2. Use of claim 1, wherein the sequence is X,XsGPX TWX; (SEQ ID NO: 48)
3. Use of claim 2, wherein said sequence is X3X,XsGPXTWX;Xg (SEQ ID NO: 1), wherein AMENDED SHEET
; PCT/US01/16654 X; is selected from C, E, A, a-amino-y-bromobutyric acid, and homocysteine (Hoc); and, Xg is selected from C, K, A, a-amino-y-bromobutyric acid, and homocysteine (Hoc).
4. Use of claim 3 with the proviso that either X; or Xg is C or homocysteine (Hoc).
5. Use of claim 4 wherein X3 or Xg is C.
6. Use of claim 3 wherein Xj is selected from C, E, and A; X, is selected from R, H, and Y, or X, is nonexistent; Xs, is selected from V, L, I, M, E, and A; and X, is D or V; and Xg is selected from C, K and A.
7. Use of claim 3 wherein said peptide is a dimer of each of said monomeric peptides comprising a sequence of amino acids YX,X3X,X;GPXTWX,X; (SEQ ID NO: 2), wherein X, and Xg are each independently selected from the 20 genetically coded L-amino acids; X53 is C; and Xg is C.
8. Use of claim 7 wherein X, is selected from L, S, H, M, A and I, or X, is nonexistent; and AMENDED SHEET i PCT/US01/16654 Xj is selected from V, L, I, M, E, and A.
9. Use of claim 7 wherein each of said monomeric peptides comprises a sequence of amino acids X YX X 3X XsGPX TWX; Xs XX 0X (SEQ ID NO: 3), wherein each of X, X,, X, Xo, X19 and X, is independently selected from the 20 genetically coded L-amino acids.
10. Use of claim 9 wherein X; is selected from C, E, and A; X, is selected from R, H, and Y, or X, is nonexistent; XyisDor V; XgisCorK X9isK,G,L,Q,R, S, or T; and Xi0is A,G,P,R, or Y.
11. Use of Claim 10 wherein X{isD,E L,N,S, Tor V; X, is selected from L, S, H, M, A, and I, or X, is nonexistent; Xy is selected from K, Q, R, §, and G; and Xp is selected from P, Y, and A.
12. Use of claim 3 wherein said peptide is a dimer of each of said monomeric peptides comprising AMENDED SHEET
; PCT/US01/16654 a sequence of amino acids X X,X;X,XsGPX,TWX,Xs (SEQ ID NO: 49), wherein X' is selected from D-Tyr, p-NO,-Phe, p-NH,-Phe, p-F-Phe, p-I-Phe, and 3,5-dibromo-Tyr.
13. Use of claim 12 wherein said sequence is X CHFGPLTWVC. )
14. Use of claim 1 wherein each of said monomeric peptides comprise a sequence independently selected from GGLYLCRFGPVTWDCGYKGG (SEQ ID NO: 7); GGTYSCHFGPLTWVCKPQGG (aka EMP-1) (SEQ ID NO: 8); GGDYHCRMGPLTWVCKPLGG (SEQ ID NO: 9); VGNYMCHFGPITWVCRPGGG (SEQ ID NO: 10); GGVYACRMGPITWVCSPLGG (SEQ ID NO: 11); ’ VGNYMAHMGPITWVCRPGG (SEQ ID NO: 2); GGTYSCHFGPLTWVCKPQ (aka EMP-16)(SEQ ID NO: 13); GGLYACHMGPMTWVCQPLRG (aka EMP-36)(SEQ ID NO: 14); : TIAQYICYMGPETWECRPSPKA (aka EMP-38)(SEQ ID NO: 15); YSCHFGPLTWVCK (aka EMP-20)(SEQ ID NO: 16); YCHFGPLTWVC (aka EMP-23)(SEQ ID NO: 17); SCHFGPLTWVCK (aka EMP-24)(SEQ ID NO: 18); GGTASCHFGPLTWVCKPQGG (aka EMP-6)(SEQ ID NO: 19); GGTYSCHFAPLTWVCKPQGG (aka EMP-9)(SEQ ID NO: 20); GGTYSCFGPLTWVCKPQGG (aka EMP-27)(SEQ ID NO: 21); TYSCHFGPLTWVCKPQGG (aka EMP-17)(SEQ ID NO: 22); TYSCHFGPLTWVCKPQ (aka EMP-18)(SEQ ID NO: 23); YSCHFGPLTWVCKP (aka EMP-19)}(SEQ ID NO: 24); YSCHFGPLTWVC (aka EMP-21)(SEQ ID NO: 25); YSCHFGALTWVCK (aka EMP-22)(SEQ ID NO: 26); GGCRIGPITWVCGG * (aka EMP-25)SEQ ID NO: 27); HFGPLTWV (aka EMP-26)(SEQ ID NO: 28); GGTTSCHFGPLTWVCKPQGG (aka EMP-7)(SEQ ID NO: 29); AMENDED SHEET
; | PCT/US01/16654 GGTFSCHFGPLTWVCKPQGG (aka EMP-8)(SEQ ID NO: 30); GGTYSCHFGALTWVCKPQGG (aka EMP-10)(SEQ ID NO: 31); GGTYSCHFGPATWVCKPQGG (aka EMP-11)(SEQ ID NO: 32); GGTYSCHFGPLAWVCKPQGG (aka EMP-12)(SEQ ID NO: 33); GGTYSCHFGPLTAVCKPQGG (aka EMP-13)(SEQ ID NO: 34); GGTYSCHFGPLTFVCKPQGG (aka EMP-14)(SEQ ID NO: 35); GGTYSCHFGPLTWVCKAQGG (aka EMP-15)(SEQ ID NO: 36); GGTXSCHFGPLTWVCKPQGG (aka EMP-28, X = D-Tyr) (SEQ ID NO: 37); GGTXSCHFGPLTWVCKPQGG (aka EMP-29, X = p-NO,-Phe) (SEQ ID NO: 38); GGTXSCHFGPLTWVCKPQGG (aka EMP-30, X = p-NH,-Phe) (SEQ ID NO: 39); GGTXSCHFGPLTWVCKPQGG (aka EMP-31, X = p-f-Phe) (SEQ ID NO: 40); GGTXSCHFGPLTWVCKPQGG (aka EMP-32, X = p-I-Phe) (SEQ ID NO: 41); GGTXSCHFGPLTWVCKPQGG (aka EMP-33, X = 3,5-dibromo-Tyr) (SEQ ID NO: 42); Ac-GGTYSCHFGPLTWVCKPQGG (aka EMP-34)(SEQ ID NO: 43); GGLYACHMGPMTWVCQPLGG (aka EMP-35)(SEQ ID NO: 44); LGRKYSCHFGPLTWVCQPAKKD (aka EMP-37)(SEQ ID NO: 45); and GGTYSEHFGPLTWVKKPQGG (aka EMP-39) SEQ ID NO: 46).
15. Use of claim 14 wherein each of said monomeric peptides is independently selected from: GGTYSCHFGPLTWVCKPQGG (aka EMP-1)(SEQ ID NO: 8); GGTASCHFGPLTWVCKPQGG (aka EMP-6)(SEQ ID NO: 19); GGTYSCHFAPLTWVCKPQGG (aka EMP-9)(SEQ ID NO: 20); and YCHFGPLTWVC (aka EMP-23)(SEQ ID NO: 17). AMENDED SHEET i PCT/US01/16654
16. Use of claim 1 wherein said peptide is a dimer formed by a polyethylene glycol linker through a covalent bond.
17. Use of claim 16 wherein each monomeric peptides of said dimer are covalently bound N- terminus to N-terminus.
18. Use of claim 16 wherein each monomeric peptides of said dimer are covalently bound N- terminus to C-terminus.
19. Use of claim 1 wherein said monomeric peptides are dimerized on activated benodiazepins, oxazalones, azalactones, aminimides or diketopiperazine.
20. Use of claim 19 wherein said monomeric peptides are covalently bound N-terminus to N- terminus. :
21. Use of claim 19 wherein said monomeric peptides are covalently bound N-terminus to C- terminus.
22. Use of claim 2, wherein the peptide comprises at least one peptide dimer.
23. A method of activating a cell surface receptor to induce neuroprotective biological activity comprising contacting a dimer of peptides of claim 2 with said receptor thereby inducing said neuroprotective biological activity.
24. The method of claim 23 wherein said cell surface receptor is contacted with said dimer in vitro or in vivo.
25. The method of claim 23 wherein said cell surface receptor is EPO receptor. AMENDED SHEET
26. The method of claim 23 wherein said peptide dimer is a cell surface receptor agonist selected form a group consisting of a GH agonist, PDGF agonist, EGF agonist, G- : CSF agonist, TPO (thrombopoietin) agonist, VEGF agonist, FGF agonist, insulin agonist, IL-3 agonist, IL-5 agonist, IL-6 agonist and IL-2 agonist. . 5
27. The method of claim 23 wherein said agonist comprises a sequence of amino acids YXXX XGPX TWX, X, (SEQ ID NO: 2) wherein each of X, and X( is independently selected from the 20 genetically coded L-amino acids; X, is C; X, is R, H, Lor W;X;isM,Forl;X;isD,E, Lor V; and X; is C.
28. The method of claim 23 wherein said agonist comprises a sequence of amino acids XY XX XX GPX TWX XXX 0X, (SEQ ID NO: 3) wherein each of X;, X,, X, X,, X,0, and X, is independently selected from any one of the 20 genetically coded L- amino acids; X; is C; X, is R,H,L or W; X;is M, For ; X, is D, E, I, L or V; and X; is C.
29. The method of claim 23 wherein said agonist comprises a sequence of amino acids XY XXX XGPX TWX, XXX, 0X, (SEQ ID NO: 3) wherein each of X,, X,, and X,1, 1s independently selected from any one of the 20 genetically coded L-amino acids; X;is C; X,isRor H; XsisForM; X is LL, T,Mor V; X;is Dor V; X, is G, K,L,Q,R,S,orT; and X,,is A, G,P,R, or Y.
30. The method of claim 23 wherein said agonist comprises a sequence of amino acids XY XXX XGPX TWX XXX 0X, (SEQ ID NO: 3) wherein X, is D,E,L,N, S, T or V; X,is A, HK, LLM, S,0r T; X; is GC; X, is Ror Hy Xs is M, F or I; X, and X|, are independently any one of the 20 genetically coded L- amino acids; X,is D, E, I, L orV; X;is C; Xp is K, R, S, or T; and X,, is P. ‘ 30
31. The method of claim 23 wherein said agonist is selected from a group consisting of: GGLYLCRFGPVTWDCGYKGG (SEQ ID NO:7); GGTYSCHFGPLTWVCKPQGG (aka EMP-1) (SEQ ID NO:8);
. 5 GGDYHCRMGPLTWVCKPLGG (SEQ ID NO:9); VGNYMCHFGPITWVCRPGGG (SEQ ID NO:10), GGVYACRMGPITWVCSPLGG (SEQID NO:11); VGNYMAHMGPITWVCRPGG (SEQ ID NO:12); GGTYSCHFGPLTWVCKPQ (aka EMP-16) (SEQ ID NO:13); GGLYACHMGPMTWVCQPLRG (aka EMP-36) (SEQ ID NO:14); TIAQYICYMGPETWECRPSPKA (aka EMP-38) (SEQ ID NO:15); YSCHFGPLTWVCK (aka EMP-20 (SEQ ID NO:16); YCHFGPLTWVC (aka EMP-23) (SEQ ID NO:17); SCHFGPLTWVCK (aka EMP-24) (SEQ ID NO:18); GGTASCHFGPLTWVCKPQGG (aka EMP-6) (SEQ ID NO:19); GGTYSCHFAPLTWVCKPQGG (aka EMP-9) (SEQ ID NO:20); GGTYSCFGPLTWVCKPQGG (aka EMP-27) (SEQ ID NO:21); TYSCHFGPLTWVCKPQGG (aka EMP-17) (SEQ ID NO:22); TYSCHFGPLTWVCKPQ (aka EMP-18) (SEQ ID NO:23); YSCHFGPLTWVCKP (aka EMP-19) (SEQ ID NO:24); YSCHFGPLTWVC (aka EMP-21) (SEQ ID NO:25); YSCHFGALTWVCK (aka EMP-22) (SEQ ID NO:26); GGCRIGPITWVCGG (aka EMP-25) (SEQ ID NO:27); HFGPLTWV (aka EMP-26) (SEQ ID NO:28), GGTTSCHFGPLTWVCKPQGG (aka EMP-7) (SEQ ID NO:29); GGTFSCHFGPLTWVCKPQGG (aka EMP-8) (SEQ ID NO:30); GGTYSCHFGALTWVCKPQGG (aka EMP-10) (SEQ ID NO:31); GGTYSCHFGPATWVCKPQGG (aka EMP-11) (SEQ ID NO:32), GGTYSCHFGPLAWVCKPQGG (aka EMP-12) (SEQ ID NO:33); ] 30 GGTYSCHFGPLTAVCKPQGG (aka EMP-13) (SEQ ID NO:34); GGTYSCHFGPLTFVCKPQGG (aka EMP-14) (SEQ ID NO:35); GGTYSCHFGPLTWVCKAQGG (aka EMP-15) (SEQ ID NO:36);
GGTXSCHFGPLTWVCKPQGG (aka EMP-28, X = D-Tyr) (SEQ ID NO:37); GGTXSCHFGPLTWVCKPQGG (aka EMP-29, X = p-NO,-Phe) (SEQ ID NO:38); GGTXSCHFGPLTWVCKPQGG (aka EMP-30, X = p-NH,-Phe) (SEQ ID NO:39); GGTXSCHFGPLTWVCKPQGG (aka EMP-31, X = p-F-Phe) (SEQ ID NO:40); GGTXSCHFGPLTWVCKPQGG (aka EMP-32, X = p-I-Phe) (SEQ ID NO:41); GGTXSCHFGPLTWVCKPQGG (aka EMP-33, X = 3,5-dibromo-Tyr) (SEQ ID NO:42); Ac-GGTYSCHFGPLTWVCKPQGG (aka EMP-34) (SEQ ID NO:43); GGLYACHMGPMTWVCQPLGG (aka EMP-35) (SEQ ID NO:44); LGRKYSCHFGPLTWVCQPAKKD (aka EMP-37) (SEQ ID NO:45); and GGTYSEHFGPLTWVKKPQGG (aka EMP-39) (SEQ ID NO:46).
32. The method of claim 23 wherein said peptide dimers are formed with a polyethylene glycol linker through a covalent bond.
33. A method of preparing a cell surface receptor agonist comprising dimerizing a cell surface antagonist.
34. The method of claim 33 wherein said cell surface antagonist receptor is a GH antagonist, PDGF antagonist, EGF antagonist, G-CSF antagonist, EGF antagonist, GM-CSF antagonist, TPO antagonist, VEGF antagonist, FGF antagonist, insulin antagonist, IL-3 antagonist, IL-5 antagonist, IL-6 antagonist, or an IL-2 antagonist.
35. The method of claim 33 wherein said cell surface receptor antagonist is an EPO-R antagonist.
36. The method of claim 35 wherein said antagonist comprises a sequence of amino acids (XX) XX XGPX TWX. X; (SEQ ID NO: 19) wherein X; is selected from the 20 genetically coded L-amino acids; X, is C; X, is R, H, L or W; X, is M, For I; X., is
- PCT/US01/16654 D, E, I, L or V; X; is C; X, is selected from the 20 genetically coded L-amino acids, n is 0 or 1 and X? is any of the 20 genetically coded L-amino acids except Y (tyrosine).
37. The method of claim 33 where said antagonist is SCHFGPLTWVCK (SEQ ID NO: 18).
38. Use of a dimer of peptides of claim 2, in the manufacture of a preparation for activating a cell surface receptor to induce neuroprotective biological activity.
39. Use of claim 38 wherein said cell surface receptor is contacted with said dimer in vivo.
40. Use of claim 38 wherein said cell surface receptor is EPO receptor.
41. Use of claim 38 wherein said peptide dimer is a cell surface receptor agonist selected from a group consisting of a GH agonist, PDGF agonist, EGF agonist, G-CSF agonist, TPO (thrombopoietin) agonist, VEGF agonist, FGF agonist, insulin agonist, IL-3 agonist, IL-5 agonist, IL-6 agonist and IL-2 agonist.
42. Use of claim 38 wherein said agonist comprises a sequence of amino acids YX, X 3X XsGPX TWX, Xs (SEQ ID NO: 2) wherein each of X, and X; is independently selected from the 20 genetically coded L-amino acids; X5 is C; X, is R, H, L or W; Xs is M,Forl; X;is D, E, I, L or V; and Xg is C.
43. Use of claim 38 wherein said agonist comprises a sequence of amino acids X YXoX3X XsGPX TWX, XXX 0X (SEQ ID NO: 3) wherein each of Xi, Xs, Xe» Xo, Xo, and X|; is independently selected from any one of the 20 genetically coded L-amino acids; X5is C; X4is R, H, Lor W; Xs is M, F or I; X;isD, E, 1, Lor V; and Xg is C.
44. Use of claim 38 wherein said agonist comprises a sequence of amino acids is independently selected from any one of the 20 genetically coded L-amino acids; X; is C; AMENDED SHEET
; PCT/US01/16654 X4isRorH; Xsis For M; Xgis, L, T, Mor V; X;is Dor V; X5 is G, K, L, Q, R, S,orT; and X,pis A, G, P, R, or Y.
45. Use of claim 38 wherein said agonist comprises a sequence of amino acids X YX, XX Xs GPX TWX 5X XX 0X (SEQ ID NO: 3) wherein X is D, E, L, N, S, T orV;X,is A, H,K,L,M, S, or T; X3is C; Xs is Ror H; Xs is M, F or I; X¢ and X; are independently any one of the 20 genetically coded L-amino acids; X;is D, E, I, Lor V; Xgis C; Xg is K, R, S, or T; and X is P.
46. Use of claim 38 wherein said agonist is selected from a group as listed in claim 31.
47. Use of claim 38 wherein said peptide dimers are formed with a polyethylene glycol linker through a covalent bond.
48. A substance or composition for use in a method for treating a subject having a condition mediated by neurotoxicity, neurodegeneration or neurological damage, said substance or composition comprising a peptide comprising one or more monomeric peptides of 8 to about 40 amino acids in length that bind to EPO receptor, each monomeric peptide comprising a sequence of amino acids X,XsX, XXX XX; (SEQ ID NO: 47) wherein the variable are as defined in claim 1, and said method comprising administering a therapeutically effective amount of said substance or composition.
49, A substance or composition for use in a method of treatment of claim 48, wherein said sequence is X,XsGPX TWX; (SEQ ID NO: 48)
50. A substance or composition for use in a method of treatment of claim 49, wherein said sequence is X3X,XsGPX,TWX,Xg (SEQ ID NO: 1), wherein Xj is selected from C, E, A, a-amino-y-bromobutyric acid, and homocysteine (Hoc); and, Xg is selected from C, K, A, a-amino-y-bromobutyric acid, and homocysteine (Hoc). AMENDED SHEET
; PCT/US01/16654
51. A substance or composition for use in a method of treatment of claim 50, with the proviso that either X5 or Xj is C or homocysteine (Hoc).
52. A substance or composition for use in a method of treatment of claim 51 wherein X; or Xg is C.
53. A substance or composition for use in a method of treatment of claim 50 wherein Xj is selected from C, E, and A; X, is selected from R, H, and Y, or X, is nonexistent; Xj; is selected from V, L, I, M, E, and A; and X; is Dor V; and Xj; is selected from C, K and A.
54. A substance or composition for use in a method of treatment of claim 50 wherein said peptide is a dimer of each of said monomeric peptides comprising a sequence of amino acids YX, XX XsGPX TWX; Xg (SEQ ID NO: 2), wherein X, and Xg are each independently selected from the 20 genetically coded L-amino acids; X53 is C; and Xg is C.
55. A substance or composition for use in a method of treatment of claim 54 wherein X, is selected from L, S, H, M, A and I, or X, is nonexistent; and Xp is selected from V, L, I, M, E, and A. AMENDED SHEET i PCT/US01/16654
56. A substance or composition for use in a method of treatment of claim 54 wherein each of said monomeric peptides comprises a sequence of amino acids X YX, X3X XsGPX TWX; Xe XoX 0X; (SEQ ID NO: 3), wherein each of X, X;, X¢, Xo, X,0 and X;, is independently selected from the 20 genetically coded L-amino acids. )
5 .
57. A substance or composition for use in a method of treatment of claim 56 wherein Xj is selected from C, E, and A; X, is selected from R, H, and Y, or X, is nonexistent; X;isDor V; XgisCorK : XyisK,G,L,Q,R, S,orT; and Xiois A, G, P,R,orY.
58. A substance or composition for use in a method of treatment of claim 57 wherein X;isD,E,L,N,S, TorV; X, is selected from L, S, H, M, A, and |, or X, is nonexistent; Xg is selected from K, Q, R, S, and G; and Xo is selected from P, Y, and A.
59. A substance or composition for use in a method of treatment of claim 50 wherein said peptide is a dimer of each of said monomeric peptides comprising a sequence of amino acids AMENDED SHEET
; PCT/US01/16654 X'X,X;3XXsGPXsTWX;Xg (SEQ ID NO: 49), wherein X' is selected from D-Tyr, p-NO,- Phe, p-NH,-Phe, p-F-Phe, p-I-Phe, and 3,5-dibromo-Tyr.
60. A substance or composition for use in a method of treatment of claim 59 wherein said sequence is X CHFGPLTWVC.
61. A substance or composition for use in a method of treatment of claim 48 wherein each of said monomeric peptides comprise a sequence independently selected from the group as listed in claim 14.
62. A substance or composition for use in a method of treatment of claim 61 wherein each of said monomeric peptides is independently selected from the group as listed in claim 15.
63. A substance or composition for use in a method of treatment of claim 48 wherein said peptide is a dimer formed by a polyethylene glycol linker through a covalent bond.
64. A substance or composition for use in a method of treatment of claim 63 wherein each monomeric peptides of said dimer are covalently bound N-terminus to N-terminus.
65. A substance or composition for use in a method of treatment of claim 63 wherein each monomeric peptides of said dimer are covalently bound N-terminus to C-terminus.
66. A substance or composition for use in a method of treatment of claim 48 wherein said monomeric peptides are dimerized on activated benodiazepins, oxazalones, azalactones, aminimides or diketopiperazine.
67. A substance or composition for use in a method of treatment of claim 66 wherein said monomeric peptides are covalently bound N-terminus to N-terminus.
68. A substance or composition for use in a method of treatment of claim 66 wherein said monomeric peptides are covalently bound N-terminus to C-terminus. AMENDED SHEET
; PCT/US01/16654
69. A substance or composition for use in a method of treatment of claim 49, wherein the peptide comprises at least one peptide dimer.
70. A substance or composition for use in a method of activating a cell surface receptor to induce neuroprotective biological activity, said substance or composition comprising a dimer of peptides of claim 2, and said method comprising contacting said substance or composition, with said receptor thereby inducing said neuroprotective biological activity.
71. A substance or composition for use in a method of treatment of claim 70 wherein said cell surface receptor is contacted with said dimer in vivo.
72. A substance or composition for use in a method of treatment of claim 70 wherein said cell surface receptor is EPO receptor.
73. A substance or composition for use in a method of treatment of claim 70 wherein said peptide dimer is a cell surface receptor agonist selected from a group consisting of a GH agonist, PDGF agonist, EGF agonist, G-CSF agonist, TPO (thrombopoietin) agonist, VEGF agonist, FGF agonist, insulin agonist, IL-3 agonist, IL-5 agonist, IL-6 agonist and IL-2 agonist.
74. A substance or composition for use in a method of treatment of claim 70 wherein said agonist comprises a sequence of amino acids YX,X3X;XsGPXTWX-Xs (SEQ ID NO: 2) wherein each of X, and X, is independently selected from the 20 genetically coded L-amino acids; Xj is C; X, is R, H, LorW; Xsis M,ForI; X; is D, E,I, Lor V; and Xg is C.
75. A substance or composition for use in a method of treatment of claim 70 wherein said agonist comprises a sequence of amino acids X| YX,X3X,XsGPX TWX; XXX; ,X, | (SEQ ID NO: 3) wherein each of X|, X,, X¢, Xo, Xo, and Xj; is independently selected from any one of the 20 genetically coded L-amino acids; X5is C; X4isR, H, Lor W; Xs is M, For I; X; is D, E, I, L or V; and Xj is C.
76. A substance or composition for use in a method of treatment of claim 70 wherein said agonist AMENDED SHEET i PCT/US01/16654 comprises a sequence of amino acids independently selected from any one of the 20 genetically coded L-amino acids; X3 is C; X, is R or H; XsisForM; Xgis I, L, T, Mor V; X;isDor V; X5is G, K, L, Q, R, S, or T; and X,, is A, G,P,R,orY.
77. A substance or composition for use in a method of treatment of claim 70 wherein said agonist comprises a sequence of amino acids X; YX,X3X, XsGPX TWX, X XX 0X, (SEQ ID NO: 3) wherein X;isD,E,L,N,S, TorV; X,is A,H,K,L,M, S,orT; X3is C; X4 is R or H; Xs is M, F or I; X and X,, are independently any one of the 20 genetically coded L-amino acids; X; is D, E, I, L or V; Xgis C; Xg is K, R, S, or T; and X; is P.
78. A substance or composition for use in a method of treatment of claim 70 wherein said agonist is selected from the group as listed in claim 31.
79. A substance or composition for use in a method of treatment of claim 70 wherein said peptide dimers are formed with a polyethylene glycol linker through a covalent bond.
80. Use according to claim 1, or claim 38, substantially as herein described and illustrated.
81. A method according to claim 23, substantially as herein described and illustrated.
82. A method according to claim 33, substantially as herein described and illustrated.
83. A substance or composition for use in a method of treatment according to claim 48, or claim 70, substantially as herein described and illustrated.
84. A new use of a peptide as defined in claim 1, or of a dimer of peptides of claim 2; a new non- therapeutic method of treatment; a new method of preparing a cell surface receptor agonist; or a substance or composition for a new use in a method of treatment, substantially as herein described. AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20765400P | 2000-05-26 | 2000-05-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200210304B true ZA200210304B (en) | 2004-03-19 |
Family
ID=22771463
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200210304A ZA200210304B (en) | 2000-05-26 | 2002-12-19 | Neuroprotective peptides. |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1296702A4 (en) |
JP (1) | JP2003534384A (en) |
CN (1) | CN1318084C (en) |
AU (2) | AU7490401A (en) |
BR (1) | BR0111182A (en) |
CA (1) | CA2410453A1 (en) |
HK (1) | HK1058484A1 (en) |
IL (1) | IL153079A0 (en) |
MX (1) | MXPA02011727A (en) |
NZ (1) | NZ522924A (en) |
WO (1) | WO2001091780A1 (en) |
ZA (1) | ZA200210304B (en) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030166003A1 (en) * | 1999-06-14 | 2003-09-04 | Cochran Andrea G. | Structured peptide scaffold for displaying turn libraries on phage |
JP2003502304A (en) | 1999-06-14 | 2003-01-21 | ジェネンテック・インコーポレーテッド | Structured peptide scaffolds for displaying turn libraries on phage |
US7078376B1 (en) | 2000-08-11 | 2006-07-18 | Baxter Healthcare S.A. | Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects |
US6914123B2 (en) | 2001-04-17 | 2005-07-05 | Genentech, Inc. | Hairpin peptides with a novel structural motif and methods relating thereto |
ES2558102T3 (en) | 2003-05-06 | 2016-02-02 | Biogen Hemophilia Inc. | Chimeric coagulation factor proteins for the treatment of a hemostatic disorder |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
US7348004B2 (en) | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
WO2004101611A2 (en) * | 2003-05-12 | 2004-11-25 | Affymax, Inc. | Peptides that bind to the erythropoietin receptor |
PT1629007E (en) | 2003-05-12 | 2009-05-06 | Affymax Inc | Novel peptides that bind to the erythropoietin receptor |
EP1626983B8 (en) | 2003-05-12 | 2010-12-22 | Affymax, Inc. | Novel poly (ethylene glycol) modified erythropoietin agonists and uses thereof |
CA2525399A1 (en) * | 2003-05-12 | 2004-11-25 | Affymax, Inc. | Novel spacer moiety for poly(ethylene glycol)-modified peptide-based co mpounds |
US7589063B2 (en) | 2004-12-14 | 2009-09-15 | Aplagen Gmbh | Molecules which promote hematopoiesis |
EP1848461A2 (en) | 2005-02-16 | 2007-10-31 | Nektar Therapeutics Al, Corporation | Conjugates of an epo moiety and a polymer |
US7550433B2 (en) | 2005-06-03 | 2009-06-23 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
EP1857463A1 (en) * | 2006-05-03 | 2007-11-21 | Ebewe Pharma Ges.m.b.H. Nfg. KG | Peptide having neuroprotective effects |
EP3669894A3 (en) | 2006-06-30 | 2020-08-26 | Syntab Therapeutics GmbH | Novel multifunctional compounds for pharmaceutical purposes |
CA2676820A1 (en) | 2007-01-31 | 2008-08-07 | Affymax, Inc. | Nitrogen-based linkers for attaching modifying groups to polypeptides and other macromolecules |
EP2018835B1 (en) | 2007-07-09 | 2014-03-05 | Augustinus Bader | Agent-eluting plaster |
BRPI1008749B8 (en) | 2009-02-05 | 2021-05-25 | Immunogen Inc | benzodiazepine derivative compounds, their conjugates, pharmaceutical composition, their use and their preparation processes |
RU2410392C2 (en) | 2009-02-16 | 2011-01-27 | Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии имени В.В. Закусова РАМН | Dipeptide mimetics of ngf and bdnf neurotrophins |
ES2632164T3 (en) | 2010-07-06 | 2017-09-11 | Augustinus Bader | Topical application of erythropoietin for use in the treatment of corneal lesions |
EP3666289A1 (en) | 2011-02-15 | 2020-06-17 | ImmunoGen, Inc. | Cytotoxic benzodiazepine derivatives |
AU2014290116A1 (en) * | 2013-07-17 | 2016-02-11 | Araim Pharmaceuticals, Inc. | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
CN105017406B (en) * | 2014-04-21 | 2020-10-09 | 上海市第一人民医院 | Novel polypeptide with neuroprotective function |
CN105233256A (en) * | 2015-10-28 | 2016-01-13 | 中国人民解放军第三军医大学 | Application of erythropoietin and erythropoietin derivatives to preparation of medicine for promoting apoptotic cell clearance during disease treatment |
GB201609083D0 (en) | 2016-05-24 | 2016-07-06 | Syntab Therapeutics Gmbh | Synthetic compound |
KR20210060536A (en) * | 2018-09-14 | 2021-05-26 | 에포-메드 가부시키가이샤 | Anti-erythropoietin receptor peptide |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5767078A (en) * | 1995-06-07 | 1998-06-16 | Johnson; Dana L. | Agonist peptide dimers |
US6165783A (en) * | 1997-10-24 | 2000-12-26 | Neuro Spheres Holdings Ltd. | Erythropoietin-mediated neurogenesis |
US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
-
2001
- 2001-05-23 NZ NZ52292401A patent/NZ522924A/en not_active IP Right Cessation
- 2001-05-23 WO PCT/US2001/016654 patent/WO2001091780A1/en active IP Right Grant
- 2001-05-23 BR BR0111182-5A patent/BR0111182A/en not_active Application Discontinuation
- 2001-05-23 AU AU7490401A patent/AU7490401A/en active Pending
- 2001-05-23 MX MXPA02011727A patent/MXPA02011727A/en unknown
- 2001-05-23 AU AU2001274904A patent/AU2001274904B2/en not_active Ceased
- 2001-05-23 JP JP2001587795A patent/JP2003534384A/en active Pending
- 2001-05-23 CA CA002410453A patent/CA2410453A1/en not_active Abandoned
- 2001-05-23 IL IL15307901A patent/IL153079A0/en unknown
- 2001-05-23 EP EP01941562A patent/EP1296702A4/en not_active Withdrawn
- 2001-05-23 CN CNB018131794A patent/CN1318084C/en not_active Expired - Fee Related
-
2002
- 2002-12-19 ZA ZA200210304A patent/ZA200210304B/en unknown
-
2004
- 2004-02-25 HK HK04101352A patent/HK1058484A1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
BR0111182A (en) | 2004-02-25 |
CN1452492A (en) | 2003-10-29 |
WO2001091780A1 (en) | 2001-12-06 |
EP1296702A4 (en) | 2005-05-11 |
EP1296702A1 (en) | 2003-04-02 |
MXPA02011727A (en) | 2003-10-24 |
NZ522924A (en) | 2004-12-24 |
IL153079A0 (en) | 2003-06-24 |
CN1318084C (en) | 2007-05-30 |
CA2410453A1 (en) | 2001-12-06 |
HK1058484A1 (en) | 2004-05-21 |
JP2003534384A (en) | 2003-11-18 |
AU7490401A (en) | 2001-12-11 |
AU2001274904B2 (en) | 2006-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001274904B2 (en) | Neuroprotective peptides | |
AU2001274904A1 (en) | Neuroprotective peptides | |
CN100441595C (en) | Novel peptides that bind to the erythropoietin receptor | |
CN1823088B (en) | Novel peptides that bind to the erythropoietin receptor | |
US9605073B2 (en) | Modulation of activity of neurotrophins | |
KR101626153B1 (en) | Tissue protective peptides and uses thereof | |
Russell et al. | Type beta transforming growth factor reversibly inhibits the early proliferative response to partial hepatectomy in the rat. | |
US7259146B2 (en) | Neuroprotective peptides | |
JP2013173763A (en) | Erythropoitein receptor peptide formulation and use | |
JP2012097118A (en) | Agonist peptide dimer | |
CN101123978A (en) | Neublastin variants | |
CN1525866B (en) | Treatment using neublastin polypeptides | |
CN101365712A (en) | Pan-her antagonists and methods of use | |
US20090170759A1 (en) | Neuroprotective peptides | |
US8138304B2 (en) | Neural regeneration peptides and formulations thereof | |
Russell et al. | Role of nerve growth factor in suramin neurotoxicity studied in vitro | |
KR102414649B1 (en) | Erythropoietin-derived peptide, preparation method therefor, and use thereof | |
JP3945846B2 (en) | Pancreatic function improving agent | |
CN101142234A (en) | Novel peptides that bind to the erythropoietin receptor | |
EP0820507B1 (en) | Ndf peptides | |
Edwards et al. | Neuregulin 1 growth factors regulate proliferation but not apoptosis of a CNS neuronal progenitor cell line | |
JP2010536858A (en) | Erythropoietin receptor peptide preparation and use | |
WO2000007611A1 (en) | Treatment of central nervous system ischemia or trauma with epidermal growth factor-like polypeptides | |
Fox | Fibroblast Growth Factor | |
Factor | Astrogliosis in Culture. IV. Effects of Basic |